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EXECUTIVE SUMMARY 
Georgia has a concentrated but growing HIV epidemic. Over the past decade, HIV 
prevalence has increased among all population groups, particularly among men who have sex 
with men (MSM).  
If current conditions (behaviors and service coverage) are sustained up to 2030, the 
epidemic is expected to stabilize among female sex workers (FSWs). At the same time, 
HIV prevalence among people who inject drugs (PWID) and the clients of female sex 
workers (FSW) may increase, but at a slower rate than in the past. Optima analyses 
suggest the necessity to invest in PWID programs, including needle-syringe programs (NSP) 
and opiate substitution therapy (OST), at a level similar to 2014 spending. Given the relatively 
high cost of OST provision, increases in coverage may require additional technical efficiency 
analyses to identify ways to reduce the average OST costs. 
MSM account for the largest proportion of new infections and experience the highest 
prevalence levels of HIV (13 percent in 2012).1 However, prevention programs that 
specifically target MSM currently account for approximately only 3 percent of HIV 
spending. Given the high HIV prevalence, increasing the resources to, and coverage of, MSM 
programs could be particularly beneficial. A large proportion of MSM in Georgia also have 
female partners 67 percent and 51 percent in 20102 and 2012,3 respectively).  
The HIV epidemic in the general population is expected to increase due largely to the 
increasing HIV prevalence among MSM and existing prevalence among PWID. Prevention 
and treatment for MSM are expected to be the most cost-effective approaches to minimize the 
downstream effects. 
The HIV epidemic among PWID in Georgia has stabilized due to significant and 
prolonged efforts to target this population. Although targeting of MSM was projected to be 
a critical component of the future HIV response, this action alone will not be sufficient to 
contain the epidemic overall, even at increased  levels. Both PWID and MSM populations 
should be targeted as much as possible through strong preventive efforts complemented by a 
comprehensive test-and-offer-treatment approach.  
Testing key populations and their sexual partners is the most cost-effective strategy to 
identify those who require antiretroviral therapy (ART). From 2004 to 2014, Georgia has 
expanded ART coverage and expects additional improvements in coverage. According to 
Optima analyses, ART will remain an essential component of the HIV response, but it alone will 
not be sufficient to halt the epidemic. Due to the high cost of testing and counselling to identify 
even one person living with HIV in a population currently experiencing low HIV prevalence, 
                                                               
1  Curatio International Foundation 2013a.  
2  Curatio International Foundation 2011. 
3  Curatio International Foundation 2013a. 
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widespread HIV testing and counselling for the general population were not part of the 
optimized mix of interventions.   
Opportunities exist to further optimize investments. The allocative efficiency of 
Georgia’s current programs could be further improved by increasing investments in ART. 
If the 2014 annual budget of approximately US$14.8 million were allocated more 
optimally among key populations and interventions, an additional 2,969 (15.5 percent of 
the current level) new infections could be prevented by 2030.  
Improvements in technical efficiency may provide additional gains. Although this 
study did not include detailed analysis of technical efficiency and unit costs, the total cost 
per person reached within Georgia’s programs suggests there could be an opportunity for 
efficiency gains by using optimized resource allocation. The National HIV Strategic Plan 
2016–20184 already aims for higher coverage at a lower unit cost in some programs. 
However, additional technical efficiency analysis is recommended, particularly for programs 
that currently absorb large proportions of HIV funding such as opiate substitution therapy 
(OST) and ART. 
The health and economic burden of HIV in Georgia is growing. If the current budget 
and combination of HIV programing continue without improvements in allocative or 
technical efficiency, HIV incidence is expected to increase. The care and treatment of 
people living with HIV in Georgia, therefore, will lead to a substantial and increasing 
burden of disease (BOD) as well as associated direct and indirect costs. Optimized 
resource allocation would reduce the number of new HIV infections. 
Figure 1 Comparing the allocation of 2014 spending against an optimized allocation of 150 percent of 
2014 spending (similar to the draft National HIV Strategic Plan budget) 
In the long term, the model predicts that HIV resource needs will increase with rising 
incidence and prevalence. However, the analysis estimates that optimizing current 
allocations by increasing spending on ART provision while sustaining investment in key 
populations could save approximately $224,635 annually. The results also show that 
                                                               
4  The national strategic plan was at a stage of final draft at the time of completion of this report. 
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optimizing the allocation of current spending would lower annual spending commitments for 
newly infected PLHIV by approximately 15 percent. 
Current annual spending will not be enough to achieve National HIV Strategic Plan and 
international targets. To fill resource gaps, additional domestic resources must be allocated 
to HIV spending. Although domestic funding for HIV in Georgia has increased since 2006, much 
of the increase has been financed through out-of-pocket expenditure by households. Reliance 
on out-of-pocket spending could delay care-seeking, increase the risk of additional infections, 
reduce the cost-effectiveness of treatment, and ultimately reduce the technical efficiency of 
HIV spending. For these reasons, transitional funding mechanisms should aim to increase state 
participation in healthcare financing. 
  
 1 
1. WHY ALLOCATIVE EFFICIENCY ANALYSIS 
NOW?  
1.1. Georgia’s health and health financing context 
1.1.1. Burden of disease 
Georgia’s overall burden of disease is characterized by a mix of significant causes of morbidity 
and mortality (Figure 1.1). There is a continued contribution of neonatal and child mortality to 
the overall number of disability adjusted life years (DALYs). In the population of reproductive 
age (15–49 years), the largest contributors are noncommunicable diseases, followed by 
injuries. In the population aged 50 years and above, noncommunicable diseases, particularly 
cardio and circulatory diseases and cancer, are the dominant causes of DALYs lost. Considering 
that the 478 DALYs directly attributable to HIV in 20105 mostly affect key populations and 
their sexual partners, HIV prevention and treatment remain important components of health 
service delivery to these populations. 
Figure  1.1 Disability adjusted life years (DALYs) due to different causes by age, 2010 
 
Source: University of Washington 2014.  
 
                                                               
5  University of Washington 2014. 
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1.1.2. Health care financing 
According to Georgia National Health Accounts (NHA) data, total health expenditure has been 
increasing since 2000, reaching US$1522 million in 2013. Private health expenditure, mainly in 
the form of out-of-pocket formal and informal payments for service at the point of delivery, 
dominates health expenditure. In 2013 an estimated 78 percent of total health expenditure 
came from private sources compared to only 22 percent from government sources (Table 1.1). 
According to World Health Organization (WHO) estimates (Figure 1.2), government health 
spending in Georgia constitutes one of the lowest proportions of total health expenditure in 
the Europe and Central Asia (ECA) Region. Although not fully explored in this report, such 
heavy reliance on private and out-of-pocket spending is likely to deter preventive care-seeking 
and may delay early detection of disease. In Georgia’s context, out-of-pocket payments 
comprise both formal fees and substantive informal fees (Chanturidze and others 2009). As 
discussed later, this reliance may result in higher treatment costs and poorer outcomes. 
Table  1.1 Trends in health expenditure in Georgia, 2006–13 
 Indicator  2008 2009 2010 2011 2012 2013 
GDP (current prices, US$ million) 12799.3 10766.8 11638.5 14434.6 15846.5 16140.0 
Total health expenditure (US$ million) 1151.9 1098.2 1175.5 1356.9 1457.9 1522.4 
Total health expenditure (US$ per capita) 260.6 249.3 266.2 310.3 332.9 349.9 
Total health expenditure as a % of GDP 9.0 10.2 10.1 9.4 9.2 9.4 
Government health expenditure as a % of total 
health expenditure  
19.8 22.3 22.8 18.1 18.0 21.5 
Private health expenditure as a % of total health 
expenditure 
80.2 77.7 77.2 81.9 82.0 78.5 
Government health expenditure as a % of total 
government expenditure 
4.8 6.1 6.6 5.3 5.2 6.7 
External resources for health as a percentage of 
total health expenditure  
10.1 5.5 2.9 2.8 3.0 2.6 
Out-of-pocket health expenditure as a % of 
private health expenditure  
80.1 85.6 89.5 79.3 78.9 78.9 
Out-of-pocket health expenditure as a % of total 
health expenditure 
64.2 66.6 69.1 64.9 64.7 61.9 
Source: WHO National Health Accounts Database, http://apps.who.int/nha/database/Select/Indicators/en. 
Figure  1.2 Government health expenditure as a percentage of total health expenditure in the ECA 
Region, 2013  
 
Source: WHO estimates from WHO National Health Accounts Database, 
http://apps.who.int/nha/database/Select/Indicators/en. 
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In Georgia, for the most part, total health expenditure as a percentage of GDP been decreasing 
since 2009. The exception was in 2013, when spending increased slightly to 9.4 percent of 
GDP. Despite the preceding decline, the 2013 percentage remains higher than in other 
countries in the Region, in which, on average, total health expenditure is 6 percent of GDP 
(Figure 1.3). Georgia’s total health expenditure as a percentage of GDP is approximately equal 
to the Organisation for Economic Co-operation and Development (OECD) country average. 
However, health expenditure in the majority of OECD countries relies less on out-of-pocket 
health spending than in Georgia. 
Figure  1.3 Trends in health expenditure as a percentage of GDP, 2000–13 
Source: WHO National Health Account Database, http://apps.who.int/nha/database/Select/Indicators/en. 
1.2 HIV epidemic is growing in Georgia 
Despite relatively low overall prevalence, the HIV epidemic remains a significant public health 
concern in Georgia. Since the detection of the first case in 1989, new HIV diagnoses in the 
country have increased steadily, reaching 10.9 per 100,000 in 2013 (UNAIDS 2013). 
Cumulatively since the onset of the epidemic, 5,127 new infections were registered in August 
2015,6 an increase from 3,641 (41 percent) at the end of 2012. Cumulatively, since the onset of 
the HIV epidemic1,037 registered AIDS deaths were recorded by August 2015.7 The HIV 
epidemic is concentrated among key affected populations: people who inject drugs (PWID); 
female sex workers (FSW); and men who have sex with men (MSM). In Georgia, the MSM 
category includes men who have sex with men and women (MSMW).  
According to Optima estimates, at least 33 percent of these key populations are not aware of 
their status as indicated by recent integrated bio-behavioral surveillance survey (IBBSS) 
findings.8 Low detection rates lead to late presentation for treatment. Late treatment adversely 
affects treatment outcomes and significantly increases short-term mortality risk. 
Approximately 50 percent of newly HIV-diagnosed persons in Georgia already have AIDS, and 
up to 70 percent of newly HIV-diagnosed patients have with CD4 cell counts of less than 350 
(WHO 2014a). Despite this relatively high rate of persons who present late for treatment, 
                                                               
6
  National AIDS Centre, http://aidscenter.ge/epidsituation_eng.html. 
7
  National AIDS Centre, http://aidscenter.ge/epidsituation_eng.html. 
8
  From the 2015 Georgia Final Draft National HIV Strategic Plan:  26.2% of MSM (73 of 278) in 2010 and 33.9% of 
MSM (74 of 218) in 2012 reported being tested for HIV in the last year according to the IBBSS study.  
0 
2 
4 
6 
8 
10 
12 
2000 2002 2004 2006 2008 2010 2012 
%
 G
D
P
 
Armenia 
Azerbaijan 
Georgia 
Russian 
Federation 
Ukraine 
4 Optimizing investments in Georgia’s HIV response 
 
mortality among HIV patients in Georgia has decreased substantially since the country made 
treatment available to all PLHIV who are eligible and diagnosed.9 
1.3 Financing the HIV response in Georgia 
From 2006-14, total HIV spending in Georgia increased nearly 140 percent (Figure 1.4). 
Current reliance on international donors for a substantive portion of HIV financing, coupled 
with an expected reduction in international assistance in the medium-to-long terms are key 
challenges to the sustainability of Georgia’s HIV programming. These challenges will be 
compounded if HIV incidence continues to rise. 
Figure  1.4 Overall spending on HIV/AIDS in Georgia, 2006–14 
Source: Prepared by the authors based on National Center for Disease Control and Public Health 2014 and the 
final draft National Strategic Plan 2016-20.  
1.3.1. Donors contribute significant but declining share of HIV funding 
As mentioned above, most HIV funding in Georgia historically has come from international 
sources. To date, the majority of funding has come from the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (Global Fund). However, the level of donor funding has varied 
substantially over time. In 2014, domestic funding, that is, combined state and out-of-pocket 
(private) spending, was marginally higher than international funding. Out-of-pocket spending 
includes only the formal contribution made by PWID who utilized opiate substitution therapy 
(OST) services at the state-funded centers.10 Because out-of-pocket spending does not include 
informal payments or payment outside of National HIV Program delivery sites, for example, for 
condoms or needles in pharmacies, it is likely to be underestimated.  
The ongoing fallout of the 2008 economic crisis has reduced the prospect of increasing or 
stabilizing the international funding for national HIV responses in the ECA Region. The Global 
Fund is the primary funding partner for key HIV programs in Georgia. As a result of the 
eligibility and cofinancing requirements of the Global Fund’s new funding model, external HIV 
                                                               
9
  From the Georgia Final Draft National HIV Strategic Plan: The all-cause mortality rate peaked in 2004, with 10.74 
deaths per 100 person-years (PY) (95% CI: 7.92–14.24) and significantly decreased after the widespread 
availability of ART to 4.02 per 100 PY (95% CI: 3.28–4.87) reported in 2012 (p < 0.0001). There was more than a 
3-fold decrease in AIDS-related mortality from 6.49 deaths per 100 PY (95% CI: 4.34–9.32) in 2004 to 2.05 
deaths per 100 PY (95% CI: 1.53–2.68) in 2012 (p < 0.0001). 
10
  The state-funded OST program is based on a cofunding principle. Copayment for the patients enrolling in these 
programs was $150 GEL/month before 2013 and was reduced to $110 GEL/month in 2013. However, these 
centers serve HIV/AIDS patients for free (USAID 2014). 
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funding is likely to decline. This likelihood leads to concern about the sustainability of 
Georgia’s long-term national HIV response. Funding partners increasingly are technically 
supporting  countries to establish transitional funding mechanisms that will facilitate the shift 
from international to domestic financing of HIV programs. 
Since 2006, the share of domestic resources spent on HIV programs in Georgia has quadrupled, 
from 10.0 percent in 2006 to 52.4 percent in 2014 (Figure 1.5). As noted, much of this increase 
in domestic funding has been financed through out-of-pocket (private) expenditure.11  
Further reducing Georgia’s dependence on external donor funding may require the 
establishment of short-term transitional funding mechanisms to supplement and redirect 
domestic funding sources to increase state participation in healthcare financing.  
Figure  1.5 Funding for HIV in Georgia, by funding source, 2006–14 (%) 
 
Source: Prepared by the authors based on National Center for Disease Control and Public Health 2014 and the 
final draft National Strategic Plan 2016-20.  
1.4 Necessity for allocative efficiency 
Current HIV programs are faced with the necessity to scale up prevention while providing 
ongoing treatment to a larger number of people living with HIV than ever before. In the 
current environment of increasingly limited resources for HIV epidemic responses, focused 
design and efficiency in program delivery are essential to ensure that programs can do more 
with less.  
To maximize the impact of program investment and best realize the long-term health and 
economic benefits of HIV programs, a shift toward investment thinking in the design of HIV 
responses is being promoted globally by UNAIDS and cosponsors. Investment cases are being 
developed by a number of countries to understand HIV epidemics as well as to design, deliver, 
and sustain effective HIV responses. In support of HIV investment cases, a group of ECA 
countries are conducting allocative efficiency (AE) analyses. In 2014 and 2015 AE analyses 
                                                               
11  National Center for Disease Control and Public Health 2014 
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were carried out in Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and 
Ukraine.12 This report summarizes the results of the analyses for Georgia.  
In addition, this report provides insights on the progress made and gaps that remain to reach 
key international commitments. In the 2011 United Nations Political Declaration on HIV and 
AIDS, countries agreed to reduce sexual and injection-related transmission by 50 percent, 
virtually eliminate mother-to-child-transmission, initiate 80  percent of eligible PLHIV on 
treatment, and end HIV-related discrimination by 2015 (UNGASS 2011). The 2014 Gap Report 
illustrated that substantial additional efforts will be required in most countries to achieve 
these targets (UNAIDS 2014c). Against this background, UNAIDS globally defined a Fast-Track 
strategy to achieve the goal of Ending AIDS by 2030 (UNAIDS 2014b). Fast Track includes new 
initiatives such as the 90-90-90 targets. They set out to achieve that 90 percent of all PLHIV are 
diagnosed; 90 percent of diagnosed PLHIV are on ART; and 90 percent of PLHIV on ART are 
virally suppressed. The Fast-Track approach also emphasizes the need to focus on the 
geographic areas and communities most affected by HIV and recommends that resources be 
concentrated on the programs that have demonstrated the greatest impact. 
In Georgia’s context, the investment case is complemented by a human rights-based approach 
to health care. Georgia is one of the countries in ECA to have signed the 2004 Dublin 
Declaration of Partnership to Fight HIV/AIDS in Europe and Central Asia. As set out in the final 
draft National HIV Strategic Plan (2015, 18), this approach will be operationalized through a 
range of methods: improved accessibility and quality of essential services (including opioid 
substitution treatment), optimized treatment regimens, strengthened surveillance and 
monitoring, removal of legislative and regulatory obstacles to effective service delivery, 
protection of human rights, and reducing stigma. All of these are significant deterrent factors 
in Georgia (USAID 2014). As is explained more fully later in the report   programs that critical 
from a rights perspective are protected from funding cuts in the optimization analysis. 
Thereby a provision is made in the model to ensures, for example, that PMTCT programs are 
maintained; that people on treatment do not lose access to that treatment; and that people 
who need treatment but are not yet on it are not denied access. 
1.4.1. Allocative efficiency in HIV  
The concept of allocative efficiency refers to the maximization of health outcomes, with the 
least costly mix of health interventions within a defined budget envelope. HIV allocative 
efficiency studies generally try to answer the question “How can a given HIV funding amount 
be optimally allocated to the combination of HIV response interventions that will yield the 
highest impact?”13  
There is wide consensus that better outcomes could be achieved in many settings with a given 
amount of HIV funding; or that given outcomes could be achieved with less HIV funding if 
resources were distributed optimally or if resources were used in the most efficient ways. 
Mathematical modeling is one way to determine optimized HIV resource allocation within 
defined budget envelopes. The HIV allocative efficiency (AE) analysis in this study was carried 
out using the Optimization and Analysis Tool (Optima). The results can be utilized to better 
serve the needs of decision makers and health planners. 
                                                               
12
  Aspects of the analytical process and the presentation of findings have been based on the Optima analyses and 
accompanying reports for six other countries in the Region. 
13  For published study reports see, for example, Republic of Tajikistan 2014 and Fraser and others 2014. 
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2. HOW WILL THIS REPORT ANSWER KEY 
QUESTIONS? 
This report summarizes how Georgia may be able to better allocate current HIV spending to 
maximize health outcomes. The findings can assist the government to strengthen its HIV 
investment case, by which it is attempting to increase the effectiveness of its HIV investments 
and define the corresponding priorities, strategies, and impacts of its HIV response.  
2.1 Optima model 
To assess HIV epidemic trends, the analysts used Optima’s epidemic module, which consists of 
a mathematical model of HIV transmission and disease progression. Optima uses best-practice 
HIV epidemic modeling techniques and incorporates evidence on biological transmission 
probabilities, detailed infection progression, sexual mixing patterns, and drug injection 
behaviors. Data relating to programs and costs associated with programs were used in an 
integrated analysis to determine an optimized distribution of investment under defined 
scenarios. 
To populate the Optima model, data from the final draft of the National HIV Strategic Plan 
2016–201814 were supplemented with published data and information from national registers. 
The model then was used to describe the likely trajectory of the epidemic in Georgia and how 
that epidemic could best be contained and treated with available financial resources. 
Optima was calibrated to HIV prevalence data points available from the different 
subpopulations (such as FSW, PWID, and MSMW) at specific time points as well as to data 
points on the number of people on ART. The calibration was performed in consultation with 
experts on the Georgian epidemic. Section 2 and appendix B provide additional details 
regarding the calibration process. 
To assess how incremental changes in spending affect HIV epidemics and thus determine the 
optimized funding allocation, the model parameterizes the relationships among the cost of HIV 
intervention programs, the coverage level attained by these programs, and the resulting 
outcomes. These relationships are specific to the country, population, and program being 
considered.  
Using the relationships among cost, coverage and outcome―in combination with Optima’s 
epidemic module―it is possible to calculate how incremental changes in funding allocated to 
each program will impact overall epidemic outcomes. Furthermore, by using a mathematical 
optimization algorithm, Optima is able to determine the “optimal” allocation of funding across 
different HIV programs.  
                                                               
14 Data and text were taken from the final draft of the National HIV Strategic Plan (March 2015), which was not the 
final National HIV Strategic Plan. Results should be interpreted accordingly.  
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2.2 Analytical framework 
To tailor the model to a given context, analysts selected a number of parameters that describe 
the country population, levels of expenditure, programs to be included or excluded, time 
frames, and baseline scenario. The parameters appropriate to the Georgian context are listed 
in Table 2.1. 
Table  2.1 Modeling parameterization  
Category Parameterization in Optima Model Description/Assumptions 
Populations defined in the 
model 
Female sex workers 
Clients of sex workers 
Men who have sex with men and women 
People who inject drugs 
Males aged 15–49  
Females aged 15–49 
Other males, aged 50+ 
Other females, aged 50+ 
Females aged 15–49 
Males aged 15–49 
Males, aged 15–49 
Males aged 15–49 
Males aged 15–49 years excluding 
MSMW, clients, and males who 
inject drugs in this age group 
Females, aged 15–49 years 
excluding FSW in this age group 
Males, aged 50+ 
Females, aged 50+ 
Expenditure areas defined 
in the model and included 
in optimization analysisa 
 
Programs for female sex workers and clients 
(package) 
Programs for men who have sex with men and 
women (package) 
Opiate substitution therapyb 
Needle-syringe program and other prevention 
for people who inject drugs (package) 
HIV testing and counselling 
Antiretroviral therapy 
Prevention of mother–to–child transmission 
Condom distribution, HIV testing 
and counselling, community 
outreach 
Condom distribution, HIV testing 
and counselling, community 
outreach 
Provision of medication and 
related counselling 
Needle and syringe exchange, 
condom distribution, HIV testing 
and counselling, community 
outreach 
HIV test kits and pre- and post-
testing counselling 
Antiretroviral drugs, related 
laboratory monitoring, and 
clinical visits 
HIV testing of pregnant women, 
counselling and provision of 
antiretroviral prophylaxis for 
women living with HIVc 
Expenditure areas not 
included in mathematical 
optimization: Indirect 
programs (because the 
effect on HIV incidence, 
morbidity/mortality not 
clear or because the 
expenditure is central 
systems expenditure 
essential for multiple 
program areas) 
Costs for indirect programs, also called enablers 
and synergies, have not been optimized (because 
they do not have measurable epidemic impact) 
but instead were fixed at agreed amounts. The 
components of HIV spending that will not be 
included in the optimization analysis are: 
Management HR and training 
Enabling environment, including legal and 
regulatory frameworks 
Monitoring, evaluation, surveillance, and 
research 
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Table 2.1 Modeling parameterization (Continued) 
Category Parameterization in Optima Model Description/Assumptions 
Time frames for which 
optimization was 
considered 
 
2000: Starting year for data entry 
2016–18: Government’s timeline to achieve 
national strategic plan targets 
2020: Interim timeline for international targets 
2030: New UNAIDS deadline to end AIDS 
 
Baseline scenario funding 2014 Global AIDS Response Progress Report 
values 
 
Note: a = “HIV testing and counselling” and “ART” programs include services for all populations (including key 
populations). HIV testing services and related outreach, which are targeted specifically at key populations, are 
included within programs for key populations; b =  Because OST has substantial benefits outside of HIV (as will 
be elaborated in the “limitations of the analysis”), a constraint was established by putting limit of 60% 
reduction in OST budget allocation (that is, not reduce the funding more than 60%) in all optimization analysis 
(analyses 1–4) to prevent the optimized budget allocation from removing or reducing allocations to OST; c = A 
comprehensive four-pronged approach to PMTCT also includes provision of contraception. For the vast 
majority of women, the primary purpose of contraception in this concentrated epidemic is not PMTCT but 
pregnancy prevention, Therefore, it was decided not to include contraception-related costs in this analysis 
(apart from the cost for condom promotion for key populations covered in FSW, MSM, and PWID programs). 
2.3 Calibration 
A key stage in the Optima modeling process is a stage known as “calibration.” Calibration aims 
to align the Optima-projected trends with the historically observed trends in HIV prevalence in 
different population groups in a given context. Given the challenges inherent in aligning 
epidemiological and behavioral data, the calibration for Georgia was performed manually (by 
varying relevant model parameters to attain the best fit between model-projected and historic 
HIV prevalence across different population cohorts) and in close collaboration with in-country 
stakeholders.  
Once the Optima model is calibrated, it can describe future expected trends in the HIV 
epidemic (chapter 3).  
2.4 Cost-coverage-outcome relationships 
The relationship between program spending and coverage is shown in the left panel of Figure 
2.1. This relationship describes the level of output achieved with a specific level of financial 
input. In the context of these analyses, output is defined as the availability of a service to a 
specific proportion of the target population. Coverage refers to the number reached in the 
population. For example, this relationship would describe how many FSW could be provided 
with a standard package of services with an investment of US$0–US$1,000,000. The 
relationship between coverage levels and outcome is shown in the right panel. This 
relationship describes the proportion of people who will adopt a specific behavior (such as 
condom use or consistent use of ARVs leading to viral suppression). These analyses were 
produced in collaboration with Georgia experts. The full set of figures can be seen in appendix 
C.  
The cost-coverage-outcome relationships are utilized, together with the calibration 
projections, to run the optimization and scenario analyses described in sections 5, 6, 7, and 8. 
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Figure  2.1 Logistic cost-outcome relationships for Georgia 
  
Note: Black dots represent available spending and coverage data, and associated behaviors. Solid curves are 
the best fitting or assumed relationships. 
2.5 Allocative efficiency analysis 
Efficiency analyses must be informed by local priorities. Georgia set the priorities for its HIV 
response in the final draft of its National HIV Strategic Plan. The plan also describes the key 
impacts, outcomes, and targets intended by end-2018. These priorities and targets are: 
a. Increase domestic funding of the HIV response from 32 percent (2013) to 70 percent 
b. Contain HIV prevalence among PWID, FSW, and prisoners at below 5 percent 
c. Hold HIV prevalence among MSM below 15 percent 
d. Reduce the rate of late HIV detection from 70 percent to 35 percent 
e. Reduce AIDS-related mortality to fewer than 2 deaths per 100,000 population 
f. Essential treatment coverage targets are shown in Table 2.2. 
Table  2.2 Georgia: Essential treatment coverage targets 
Percentage of adults and children with HIV known to be on treatment 12 months after initiating 
treatment among patients initiating antiretroviral therapy 
90 
Percentage of newly diagnosed persons who are enrolled in care >90 
Percentage of people on ART tested for viral load (VL) with VL level ≤ 1000 copies/ml after 12 
months of therapy 
85 
Number and percent of adults and children receiving antiretroviral therapy according  
to the nationally approved treatment protocol at the end of the reporting period 
4,800 
 59* 
Source: Government of Georgia 2015, 28. 
Note: * = Denominator is based on the Spectrum estimates and will be changed in line with the regular 
Spectrum updates.  
To support the National HIV Strategic Plan priorities and assist Georgia in meeting its targets, 
this report answers four questions:  
1. How can Georgia optimize the allocation of its current HIV funding?  
2. What might be gained from increased investment in HIV programming? 
3. What is the minimum spend that would be required to meet the National HIV Strategic 
Plan targets?  
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4. What are the long-term resource needs of Georgia’s HIV response? This question refers to 
the liabilities arising from the commitment to provide HIV and related health services in 
the future.  
Each of these questions is the subject of an analytical module detail below. 
Analysis 1: How can Georgia optimize the allocation of HIV funding? 
Analysis 1 compares the trajectory of the epidemic and key outcomes under the current 
allocation of resources against an optimized allocation of resources. For this analysis, the 
funding levels are not varied—only the way that funding is spent. The aim is to determine how 
Georgia can allocate available resources to achieve maximum impact, and how close this 
maximum impact will be to the National HIV Strategic Plan targets described.  
Analysis 1 asks the following specific questions:  
What will be the expected annual levels of HIV incidence, HIV prevalence, and AIDS-related 
deaths if current funding allocations are maintained? The results of this analysis are described 
in section 3 and explored in section 5. 
If funding is kept at the same level, but resources are allocated differently according to the 
optimization model, what will be the expected annual levels of HIV incidence, HIV prevalence, 
and AIDS-related deaths?  
The results of this analysis are described in section 6. 
Analysis 2: What might be gained from increased investment in HIV programs? 
Analysis 1 is was based on maintaining current funding allocations. In contrast, Analysis 2 
explores what could be achieved by increasing the available budget. Analysis 2 aims for the 
maximum possible reduction of new deaths and infections. The results appear in section 7. 
Analysis 3: What is the minimum spend required to meet the National HIV 
Strategic Plan targets? 
Analysis 3 identifies the minimum resource requirements to achieve the National HIV Strategic 
Plan targets. This analysis assesses the gaps in funding required to achieve the national targets. 
The results appear in section 8. 
Analysis 4: What are the long-term financial commitments to the HIV response? 
Analysis 4 reviews the impact of current investment choices on long-term financial 
commitments. This analysis compares the commitments expected to result from the current 
allocation of the 2014 budget against the optimized allocation of the 2014 budget described in 
section 6. The findings from this analysis are presented in section 9. 
2.6 Limitations of the Optima analyses 
All mathematical models have their strengths and limitations. Results should therefore be 
interpreted with the necessary caution. In particular, it is important to note that: 
All model forecasts are subject to uncertainty. Therefore, point-estimates are indicative of 
trends rather than exact figures. 
The model calibration depends as much on the quality of input data as on the quality of the 
model itself. The country and study teams have done everything possible to ensure the best 
possible data quality but it is never possible to have a complete, or completely certain dataset. 
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The best model calibration rarely will achieve an exact match with historical data, but will 
mirror as closely as possible their key trends. 
There were some data gaps in Georgia. Missing data are most common for the general 
population and for the clients of sex workers. As in other models, estimates of HIV prevalence 
in the general population were derived from data in pregnant women as a proxy for 
prevalence in the female general population. The average overall population prevalence value 
was used for the male general population. There were no data available for clients. Therefore, 
an assumed population size of 10 percent of the general adult male population (15–49 age 
group) was used.  
The modeling approach used to calculate relative cost-effectiveness among programs includes 
assumptions about the impact of increases or decreases in availability of funding for programs. 
These assumptions are based on unit costs and observed ecological relationships between 
outcomes of program coverage or risk behavior and the amount of money spent on programs 
in the past, assuming that increases in spending would cause some saturation in the possible 
effects of programs.  
Where possible, the cost-coverage-outcome relationships were derived from actual cost and 
coverage values as well as from the expected cost and coverage values based on the final draft 
of the National HIV Strategic Plan 2016–2018. 
The analysis presented in this report does not determine the technical efficiency of programs 
because technical efficiency was outside the scope of the analysis. However, gains in technical 
efficiency would lead to lower unit costs and therefore would affect the optimized resource 
allocation described in this report.  
Modeling the optimization of allocative efficiencies depends critically on the availability of 
evidence-based parametric estimates of the effectiveness and cost-efficiency of individual 
interventions. Interventions/programs for which these parametric estimates do not exist, such 
as for many of the critical enablers, will be excluded from the mathematical optimization 
analysis. However, their exclusion does not mean that these programs should not receive 
funding. In addition, there are uncertainties around parameter estimates of some of the critical 
clinical interventions (such as ART and the parameter estimates such as the preventive effect 
of ART). These uncertainties could distort the results. 
Effects of the programs outside the HIV endpoints are not included in this model. Such 
programs include the wider health and non-health benefits of OST (beyond those directly 
related to HIV) and the effects of needle exchange programs on hepatitis, Given that, in the case 
of OST, there are significant benefits beyond HIV outcomes, the optimized budget allocation 
was prevented from removing or reducing allocations to OST by limiting the percent reduction 
in OST budget allocation (that is, not reducing the funding more than 60 percent).  
Along the same lines, the Optima modeling approach does not seek to quantify the human 
rights; stigma and discrimination; or ethical, legal or psychosocial implications of providing or 
withdrawing care. However, the authors acknowledge that these are important aspects to 
consider. 
Other models may produce different projections than these produced by Optima. Differential 
results are an underlying property of using differing designs of theoretical mathematical 
frameworks. However, the estimates presented in this report are not significantly different 
from the epidemic trends projected in the UNAIDS estimation process using the Spectrum 
model. In addition, the analyses presented in this report have made use of the best available 
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country data, experience gained from applying the Optima model in over 20 countries, and 
comparisons within the ECA Region for the validation and contextualization of inputs and 
findings wherever possible. 
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3. WHAT ARE THE EXPECTED TRENDS IN THE 
EPIDEMIC IF CURRENT SPENDING IS 
MAINTAINED?  
3.1 Status of the epidemic 
In 2013 the estimated rate of new diagnosis in Georgia was 10.9 per 100,000 (Georgia 2014). 
At the end of 2014, 4,695 PLHIV were registered.15 According to Spectrum, the model-
estimated number of PLHIV in 2014 is 6,800.16 Results from the Optima analysis for the same 
year suggest that the number was 6,300 (Figure 3.1). The 2013 HIV prevalence among the 
general population was estimated at 0.07 percent (NCDC 2014). Table 3.1 shows the 
population sizes and the rates among key affected populations.  
Table  3.1 Population size estimates and prevalence among key affected populations, most recent 
year available 
Population Population size (most recent value) 
Prevalence  
(most recent value) (%) 
FSW 6,525a 1.30b 
Clients  (est.) 111,000 (est.) 0.12 
MSMW 17,215c 13.00d 
PWID 45,000e 3.00f 
Note: a Curatio International Foundation and Centre for information and counseling on reproductive Health – 
Tanadgoma. 2014a; b = Curatio International Foundation and Centre for information and counseling on 
reproductive Health―Tanadgoma 2013c; c = Curatio International Foundation and Centre for information and 
counseling on reproductive Health – Tanadgoma 2014b; d = Curatio International Foundation and Centre for 
information and counseling on reproductive Health - Tanadgoma 2013a; e = Curatio International Foundation 
and Public Union Bemoni, 2012; f = Curatio International Foundation and Public Union Bemoni 2013b. 
On the current trajectory, maintaining current levels of funding and current allocations to 
programs—the total number of PLHIV is projected to increase to 7,900 by 2020 and to 9,900 
by 2030 (Figure 3.1). This projection is based on an expected increase in incidence and a 
projected decrease in the death rate among PLHIV due to the positive effect of ART. The 
majority of new PLHIV will be MSMW because the prevalence in this group is projected to 
continue to increase over the next 15 years (Figure 3.1). 
While the number of deaths currently is low, that, too, is expected to rise. The remainder of 
this chapter describes these modelled projections based on the results of the calibration (see 
also appendix B. 
  
                                                               
15
  National Aids Centre. http://aidscenter.ge/epidsituation_eng.html. 
16
  Spectrum /Epidemic Projection Package 2014, vers. 5.03. 
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Figure  3.1 Calibration of PLHIV, 2000–30 
 
3.2 HIV prevalence is expected to increase 
Overall HIV prevalence is projected to increase from modelled-estimates of 0.18 percent in 
2014 to 0.23 percent in 2020 and 0.28 percent by 2030. HIV prevalence in the MSM population 
increased from 7 percent in 2010 to 13 percent in 2012, and the model predicts an increase to 
18 percent by 2020 and 20 percent by 2030. HIV prevalence is expected to virtually stabilise 
among FSWs and in keeping with stabilising prevalence among FSWs, prevalence among FSW 
clients is also projected to stabilise. However, there is significant uncertainty around this 
finding due to the lack of primary data on this key population described in chapter 2. The 
model estimates that prevalence among PWID could still increase but at a slower rate than in 
the past, due in part to decreasing rates of needle sharing. The model estimates that, if current 
conditions are maintained, HIV prevalence in this population will stabilize at approximately 3 
percent after 2014, and could increase again moderately by 2030. To maintain this expected 
trend, keeping rates of needle sharing low is essential. 
3.3 HIV Incidence is increasing 
One of the main factors underpinning the increase in HIV prevalence described above is an 
expected increase in HIV incidence (the number of new infections per year). Since 2000, 
overall incidence has increased. The model predicts that, during 2014–30, incidence will 
increase from 580 new infections per year in 2014 to 679 new infections per year in 2020, and 
to 860 per year by 2030 (Figure 3.2). These projections are consistent with the rising number 
of new HIV diagnoses in Georgia. Much of the expected increase in incidence is driven by the 
share of transmission attributed to unprotected sex between MSMW and their male and female 
partners. Low condom use between MSMW and commercial partners is a particular cause for 
concern.17 The high probability of sex between MSM and female partners also implies a 
                                                               
17  The proportion of MSM who reported condom use at their last anal insertion with a paid partner was 67% (8/12) 
in 2010 and 50% (4/8) in 2012. Given that the denominator for paid partners is very small, this proportion 
should be interpreted with caution. (Curatio International Foundation 2013a)  
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potential for increasing HIV incidence among these female partners who will be difficult to 
reach with programs, as their background characteristics are likely similar to the wider female 
adult population. . 
Figure  3.2 Calibrated number of new HIV infections per year, 2000–30 
 
3.4 AIDS-related deaths are low but increasing in number  
Until 2010, the number of AIDS-related deaths was estimated to be low and stable, reflecting 
the low-level epidemic of the 1990s. However, the number of deaths is projected to increase 
with the expanding key population epidemics of the past decade.  
ART has slowed the increase in AIDS-related mortality. However, overall, with the current 
coverage of ART, the number of deaths attributable to HIV is predicted to increase from 170 
per year in 2014 to 270 in 2020 and 400 by 2030 (Figure 3.3).  
HIV testing and ART provision are funded by the state and the Global Fund to Fight AIDS, 
Malaria and Tuberculosis (Global Fund).18 Nevertheless, poorer outcomes on ART will be 
caused, at least in part, by the late presentation for testing and treatment described earlier in 
this report and again in section 4. 
  
                                                               
18  National Center for Disease Control and Public Health 2014. 
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Figure  3.3 Calibration-predicted number of deaths due to HIV in Georgia, assuming stable coverage of 
programs, 2000–30 
 
3.5 Number of people requiring HIV treatment will increase 
Table 3.2 shows the ART coverage in Georgia from 2011 to 2014. The World Health 
Organization (WHO) 2013 treatment guidelines are to commence treatment when a patient’s 
CD4 count drops below 500 and to adopt a universal access approach. Following this approach 
has enabled Georgia to achieve a high treatment coverage of PLHIV who are eligible for 
treatment. However, the large difference in the numbers on treatment and the estimated 
population in need suggests a sizeable treatment gap.19  
Table  3.2 ART coverage in Georgia, 2011–14 
Year 
Number of PLHIV on ART Coverage among diagnosed Spectrum-derived coverage 
National 
target 
Actual 
achievement 
Number 
eligible 
(CD4<350) 
Covered from 
eligible PLHIV 
(%) 
Total 
estimated 
number of 
PLHIV 
From total 
estimated 
PLHIV 
(%) 
2011 1,290 1,245 1,295 96 5,400 23 
2012 1,540 1,640 1,750 94 5,900 28 
2013 1,820 2,092 2,300 91 6,400 33 
2014 2,110 2,541  2,675 95 6,800 37 
Source: Georgian Final Draft National HIV Strategic Plan, 11. 
                                                               
19  In 2012, 70.4% of newly identified HIV infected people had a CD4 count of <350cells/mm3 and 43.9% of these 
had a CD4 count of <200 cells/mm3 (WHO Europe 2014). 
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4. WHAT ARE THE IMPACTS OF PAST AND 
CURRENT SPENDING? 
4.1 Prevention receives the majority of current funding  
To date, prevention has been the largest component of HIV spending to date (Figure 4.1). 
Within prevention, harm reduction programs for PWID (including OST and NSP) comprise the 
largest component, ranging from 54 percent to 73 percent of prevention expenditure. In 2014, 
70 percent of prevention spending was allocated to harm reduction programs. 
Past investment in programs specifically targeting MSM and FSWs has been relatively low.20 
These investments also have varied substantially over time, suggesting a fragile financing 
climate for individual programs. In 2014, targeted programs for MSM and FSWs were allocated 
5 percent and 3 percent of prevention funding, respectively.21Table 
Figure  4.1 HIV expenditure in Georgia by type of spending, 2006–14 
 
Source: National Center for Disease Control and Public Health, 2014; Government of Georgia, 2015; Data is 
based on annual national AIDS spending assessments and the country’s Global AIDS Progress Reporting 
(GARPR). 
                                                               
20  Because many services for key affected populations are not allocated in population-specific budgets, these 
numbers may not include some spending targeted at the general population, which also benefits key affected 
populations.  
21  GARPA 2010–14 and Final Draft National HIV Strategic Plan 2014. Data has been taken from the final draft of the 
National HIV Strategic Plan (March 2015), not the final National HIV Strategic Plan. Results should be interpreted 
accordingly. 
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The proportion of spending allocated to indirect costs such as management and human 
resources has decreased since 2006. In 2014, these costs comprised approximately 9 percent 
of total HIV spending.22 
4.2 Prevention could be better targeted within and among key 
populations 
HIV prevention and treatment may not cover those in most need (Figure 4.2). Model-based 
estimates suggest that incidence and prevalence are increasing among males and females 15–
49 (who include sexual partners of PWID, MSM, and FSW and their clients) and some key 
populations, especially MSM. These trending increases suggest that prevention could be better 
targeted at MSM, including MSMW. If the role of this population in “bridging” is considered 
further, then the case for better, and better targeted, prevention is compelling because it would 
likely yield benefits for both high- and low-risk populations. 
Although the increase in prevalence among PWID is expected to be small, Optima analyses 
suggest that a need remains to invest in programs for PWID, including needle-syringe 
programs (NSP) and opiate substitution therapy (OST). However, given the relatively high 
current cost of OST provision, increases in coverage may require additional technical efficiency 
analyses to identify ways to reduce the average OST costs. 
Figure  4.2 Trends in spending across key priority prevention and treatment programs, 2010–14  
 
Note: HTC and ART are programs for the whole population so include people from key affected population 
groups. 
Using the cost-coverage relationships, the unit costs at the current level of spending (2014) 
were derived. The unit costs for some programs, in particular OST, are high when compared 
with data for other countries in the Region (Table 4.1).  
A more detailed review of these unit costs and a targeted technical efficiency analysis may be 
beneficial after this analysis has been completed. If high unit costs are reduced without 
compromising the quality of programs, then a clear efficiency gain is achieved, and “saved” 
resources can be used more effectively to combat the epidemic through reallocation to other 
programs. 
                                                               
22  Expenditure data drawn from the GARPA 2010–14 and Final Draft National HIV Strategic Plan 2014. Data has 
been taken from the final draft of the National HIV Strategic Plan (March 2015), not the final National HIV 
Strategic Plan. Results should be interpreted accordingly. 
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Table  4.1  Comparing costs of programs in the ECA Region (US$)  
Cost per person reached 
Georgia, 
2014a 
Regional comparisonb Georgia draft 
national 
strategyc Lowest Highest Average Median 
FSW programs  166.30   34.13   166.24   93.11   103.65   112.03  
MSM programs  232.35   13.46   449.13   142.09   47.79   133.99  
PWID-NSP programs  64.75   40.90   129.25   104.88   66.86   79.02  
OST  1,645.24  378.17  1,645.24   700.43   645.31   1,835.18  
PMTCTd  8,905.27  738.08  8,905.27  4,616.80  4,267.59   7,147.23  
ART  1,464.71  576.48  2,278.52  1,203.26  1,127.29   1,410.97  
Note: Table 4.1 reflects how costs were categorized by countries for this analysis. The method is not based on 
detailed matching of classification of inputs, but on how countries classified expenses using the detailed 
available guidance for NASA and GARPR reports. Although this guidance is detailed and specific, differences 
cannot be ruled out, particularly regarding cross-cutting costs such as HR costs. In addition, even if costs are 
classified consistently, the comprehensiveness of service packages may differ; a = Data were based on the 
country’s data collection for the 2014 Global AIDS Response Progress Reporting; b = The completed Optima 
data matrixes for 7 ECA countries were compiled by the study team from a range of country-specific data 
sources during 2014–15. These data are based primarily on coverage data from program records for 2013 and 
total HIV spending for a program area per 2013 GARPR and NASA reports; c = Georgia Final Draft National 
Strategic Plan 2014. Data were extracted from the final draft of the National HIV Strategic Plan (March 2015), 
not the final National HIV strategic plan. Results should be interpreted accordingly; d = A comprehensive four-
pronged approach to PMTCT includes providing contraception. Because the primary purpose of contraception 
for the vast majority of women in this concentrated epidemic is not PMTCT but pregnancy prevention, it was 
decided not to include contraception costs (apart from the cost for condom promotion for key populations 
covered in FSW, MSM, and PWID programs) in this analysis. 
A number of limitations of the data presented in Table 4.1 should be noted, along with 
additional detail about the data used. In particular: 
 Spending data for PMTCT in Georgia is an average for 2010–14 because 2013 was an 
outlier in the dataset 
 Although all expenditure data has been extracted from NASA/GARPR reports, which follow 
a standard methodology, countries may not have classified all costs in the same way 
 Coverage definitions and packages may differ among countries. 
Consequently, Table 4.1 does not provide information about which countries deliver services 
more efficiently. This analysis seeks only to highlight which programs could benefit from an 
additional, more robust review of technical efficiency. 
4.3 Investing in an HIV response averts infections and deaths 
Model-based projections of the epidemic indicate that current spending on HIV prevention and 
treatment programs will continue to avert new infections and deaths. In the absence of any 
spending on the HIV epidemic, the model estimates that prevalence would be 0.54 percent 
higher; 793 more deaths would occur; and 4,224 more people would be infected (Figure 4.3). 
Furthermore, as noted above, the total number of PLHIV is projected to increase to 7,865 by 
2020 and to 9,913 by 2030 (Figure 3.1). These projections highlight the necessity to continue 
investing in the HIV response.  
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Figure  4.3 Model-estimated impact of current spending compared to no spending on the HIV 
response, 2015–30a 
 
 
Note: a = “No spending” assumes that there is no spending on the HIV response. “Current spending” assumes 
that current funding levels and allocations remain stable and achieve coverage in line with the cost-coverage-
outcome curves defined in the model.  
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5. PREDICTING THE TRAJECTORY OF THE HIV 
EPIDEMIC: COMPARING HIV RESPONSE 
SCENARIOS  
In the previous section, the study team compared current spending levels and allocations, 
against a “no spending” scenario. Figure 4.3 demonstrated that the current response to the 
epidemic is significantly reducing HIV prevalence, HIV incidence, and HIV-related mortality 
from the levels could be expected in the absence of current programs. The Optima model 
predicts that this positive impact is likely to persist, and even grow, in the period up to 2030. 
In this section, the study team ask whether reaching pre-specified targets could further reduce 
prevalence, incidence, and mortality. Here the study team compares the trajectory of the HIV 
epidemic by 2030 in Georgia under the current HIV response against 3 alternative HIV 
response scenarios. These are not constrained by a budget but are determined solely by 
targets. These scenarios were identified through extensive consultation with local 
stakeholders and a range of experts. In this section, the epidemic trajectory is predicted for 
each of these scenarios and compared with the trajectory under current programs without 
determining the overall budget envelope required to achieve defined targets in each scenario. 
The three response scenarios used for comparison were:  
1. Test and offer treatment only (no prevention programs). This scenario assumed that, by 
2030, 90 percent of PLHIV will be aware of their status and 90 percent of PLHIV will be on 
ART.23 
2. Reaching National HIV Strategic Plan targets. This scenario assesses the trajectory of the 
HIV epidemic using the National HIV Strategic Plan (2016–18) targets for key priority 
prevention and treatment programs. 
3. Reaching the National HIV Strategic Plan targets with a larger focus on MSMW population 
by increasing condom use from 73 percent to 85 percent among the MSMW population. 
Table 5.1 presents detailed information on parameters and targets specified in the alternative 
scenarios.  
  
                                                               
23
 Treatment efficacy in reducing new infections for PLHIV on ART was assumed to be 70%.  
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Table  5.1 Parameters and target values used in the alternative scenarios, 2014-2030 
Target 
population Parameters 
Alternative response scenarios* 
Test and offer 
treatment only 
(baseline-2030) 
National 
Strategy 
(baseline-2018) 
(%) 
National Strategy 
+ MSM (baseline-
2018) 
FSWs (%) 
Proportion of sexual acts in which 
condoms are used with 
commercial partners 
No change (91) 91–95 
Same as national 
strategy scenario 
Year N/A 20–50 
Same as national 
strategy scenario 
Clients of sex 
workers (%) 
Proportion of sexual acts in which 
condoms are used with 
commercial partners 
No change (91) 91–95 
Same as national 
strategy scenario 
MSMW (%) 
Proportion of sexual acts in which 
condoms are used with casual 
partners 
No change 
(73 ) 
73–77 73–85 
Proportion of people who are 
tested for HIV each year 
N/A 10–50 
Same as national 
strategy scenario 
PWID (%) 
Proportion of people who are 
tested for HIV each year 
N/A 43–60 
Same as national 
strategy scenario 
Proportion of injections using 
receptively shared needle 
syringes 
5 5–3 
Same as national 
strategy scenario 
Number of people on OST 2,890 2,890–4,000 
Same as national 
strategy scenario 
Female 15–49 
years 
Proportion on PMTCT (%) 86 86–90 
Same as national 
strategy scenario 
Proportion of PLHIV on ART (%) 40–81 40–68 
Same as national 
strategy scenario 
Proportion of people aware of their status (%) 60–90 N/A N/A 
Note: * = Baseline data in each scenario are from different years when the latest data were available. 
The model-predicted evolution of annual HIV prevalence, incidence, and deaths (2000–30) 
under these conditions are shown in Figures 5.1, 5.2, and 5.3. Figure 5.4 shows the expected 
prevalence among MSMW for the same period, for each scenario.24 
                                                               
24 Whether the curve covering the historical period until 2014 in all scenarios is a calibration output should be 
considered. 
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Figure  5.1 Model-predicted evolution of annual HIV prevalence under different scenarios, 2000–30  
Figure  5.2 Model-predicted evolution of annual HIV incidence under different scenarios, 2000–30 
   
With the 2014 levels and allocations of funding maintained,25 prevalence, incidence, and the 
number of deaths are expected to increase. As described earlier, these increases are driven 
primarily by the rising incidence among MSMW. 
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  An annual budget of $14,757,759. 
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Figure  5.3 Model-predicted evolution of annual HIV-related deaths under different scenarios,  
2000–30 
  
Figure  5.4 Model-predicted prevalence for MSMW under different scenarios, 2000–30  
 
Source: Populated Optima model for Georgia. 
The scenario analyses demonstrate that allocating spending to a combination of National HIV 
Strategic Plan targets and improving condom use among MSMW (Option 3 above) are more 
effective in reducing overall HIV incidence than the alternative options and are projected to 
reduce incidence by an estimated 40 percent by 2030. Option 3 is also the most effective in 
containing prevalence among MSMW (Figure 5.4). Moreover, in reducing the number of deaths 
over time, each of the three alternative scenarios (Options 1–3) is significantly more effective 
than the current HIV response spending allocation. 
This scenario analysis explores different levels of achievement of program outcomes. In this 
section, the team analyzes the epidemic impact if specific outcome levels or targets are 
achieved, regardless of cost and coverage considerations. This approach differs from the 
optimization analysis in the next section, which is based on the cost-coverage outcome curves 
(CCOCs). In the optimization analysis presented next, the analysts consider the effects of 
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different levels of spending on programs, which then translate into coverage and outcomes 
according to the CCOCs. Although the CCOCs are informed by projected National HIV Strategic 
Plan costs and targets, they also consider other information such as past spending, coverage, 
and outcomes. 
 28 
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6. WHAT CAN BE IMPROVED BY OPTIMIZING 
EFFICIENCIES UNDER CURRENT FUNDING? 
An optimization analysis was conducted comparing the allocation of the current budget in 
2014 of $14,757,959 and an optimized allocation of the same budget for 2015–30. 
Overall, prevalence among the low-risk general population in Georgia is still very low. 
However, the Georgian epidemic clearly is categorized as a concentrated epidemic. Current 
(2014) HIV spending in Georgia is distributed across a wide range of HIV programs. According 
to model-based analyses, using 2014 as the baseline year, the current distribution of funding is 
different from an optimized allocation that minimizes both new infections and deaths (Figure 
6.1, Figure 6.2, and Table 6.1). Optimization of the 2014 budget to reduce HIV incidence and 
deaths averts an estimated 2,969 (15.5 percent) additional HIV infections (mainly among 
MSMW) and 2,238 (36 percent) additional deaths from 2015 to 2030. To achieve these gains, 
the following key changes are proposed: 
 ART provision should be increased.  
∙ This shift in spending reflects the relatively high effectiveness of ARVs as both treatment 
and prevention, since PLHIV on treatment have significantly reduced infectiousness. This 
intervention will reduce incidence and prevalence across all key population groups. 
Where funding is diverted from programs that target these key groups, some of the 
optimized budget is “reincorporated” here.  
 ART cannot be scaled up unless PLHIV are diagnosed.  
∙ It is therefore necessary to ensure that adequate funding remains allocated to testing, 
especially among key population groups. 
 Spending on low-risk populations (such as HTC) could be more effectively diverted to 
comprehensive HIV programs. 
∙ In Georgia, low-risk populations are large, and their individual risk of contracting HIV is 
low. It therefore is more efficient in contexts such as this to target key affected 
populations who tend to be smaller, more concentrated, and with higher individual risk 
of infection. Such a focused approach would not, and should not, stop the provision of 
testing and treatment for low-risk individuals seeking care. Figure suggests that the new 
allocation to HTC would be less than 0.1 percent of the total budget, while the allocation 
to treatment would increase overall.  
 Investments in MSMW programs should be maintained.  
∙ This population group has the highest prevalence, and individuals from key affected 
populations may infect partners in the low-risk population. Targeting key populations, 
therefore, has benefits for both high- and low-risk populations but constitutes a more 
efficient financial investment, as explained above. Since the epidemic in the low-risk, 
general population is too small to be self-sustaining without the increased risk from 
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“bridging” individuals in key, higher risk populations, the most effective strategy is likely 
to be the targeting of infections among key populations such as MSMW.  
 Investments in and coverage of NSP interventions could be largely maintained, but the 
proportion of total spending reduced, from current levels. 
∙ Maintaining, but not substantially increasing investment into NSP is in line with current 
low rates of needle-sharing rates in Georgia, and the stabilizing epidemic among PWID. 
The favorable status is attributable to the strong historical focus on this key population. 
 Recommendations for OST spending should be interpreted with caution. 
∙ OST is defined by UNAIDS and the WHO as one of the essential service components for 
PWID HIV harm reduction programs. The Optima model considers only benefits to HIV 
patients. Consequently,  service components such as OST that have significant wider 
benefits to the PWID population and to national public health may be undervalued 
(chapter 2). Therefore, any recommendations for the reduction of spending on OST 
programs should be interpreted with caution.  
The model thus suggests that, when compared to the current budget allocation, allocating 
current funding differently could further reduce the spread of the epidemic. However, with a 
larger budget envelope, it may be possible to avert additional new infections and deaths. The 
potential gains to increased investment in HIV programming are elaborated in the following 
section. 
Figure  6.1 Comparison of current and optimized budget allocation to minimize both new infections 
and deaths for 2015–30 (%) 
 
 
Source: Populated Optima model for Georgia.  
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Table  6.1 Current and optimized 2014 budget allocations 
 
Current 
allocation (US$) (%) 
Optimized 
allocation 
(US$) (%) 
FSW programs 285,772 1.9 9,049 0.1a 
MSM programs 403,818 2.7 339,213 2.3 
OST 3,948,587 26.8 2,369,152 16.1 
NSP 1,996,964 13.5 1,260,096 8.5 
HTC 688,716 4.7 1,021 0.0b 
ART 3,793,600 25.7 7,176,744 48.7 
PMTCT 39,484 0.3 1,667 0.01c 
MGMT 141,034 1.0 141,034 1.0 
HR 502,262 3.4 502,262 3.4 
ENV 499,401 3.4 499,401 3.4 
M&E 368,748 2.5 368,748 2.5 
Other 2,078,226 14.1 2,078,226 14.1 
Total 14,746,612 100.0  14,746,612 100.0 
Source: Populated Optima model for Georgia. 
Note: a = As explained in the narrative, these programs remain important from an epidemiological point of 
view and should continue to be provided, by either increasing overall funding for the HIV response or reducing 
unit costs; b = HIV testing and counselling would continue to be provided as part of programs for key 
populations. Other persons requesting to be tested for HIV also should continue to receive the service, even if 
they are not part of key populations. The model suggests that, from a cost-effectiveness perspective when no 
additional resources are available, expanded testing for the general population is not among the most cost-
effective programs; c = Pregnant women should continue to be covered with ART as part of the increased ART 
budget. In practice, covering their ART also would require continued HIV testing and counselling for pregnant 
women, which also could be financed from maternal health budgets. 
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7. WHAT MIGHT BE GAINED OR LOST FROM 
CHANGES IN HIV SPENDING AND 
ALLOCATION? 
This analysis considers what could be gained by increasing the HIV budget from 2014 levels. 
Conversely, the analysis also considers which programs would have the largest impact on the 
epidemic if less funding were available and the response needed to be further rationalized. 
Optimized allocations to programs and the corresponding impacts are compared in this 
analysis for different funding levels. 
Given a contraction of funding below the 2014 funding level, optimization suggests that ART, 
OST, and NSP should be given first priority, followed by programs that target MSMW. This 
finding is the result of a combination of factors. ART is essential to minimize deaths and 
contributes to reduce incidence. For prevention, sustaining low rates of needle-sharing and 
increasing condom use among MSMW are epidemiologically important factors given the key 
role of these two populations in transmission. The results also are partially due to the fact that 
the model construct protects funding for OST services. The protection is based on the rationale 
that nobody on OST should go off OST. OST has substantial benefits outside of HIV as explained 
in the remarks on the model in section 2. Therefore, 60 percent of OST cost was protected from 
reductions. Looking exclusively at HIV outcomes, this explicit rationing may not be desirable 
since easily preventable HIV infections will occur within such a tight funding context. Since 
OST funding is protected, efforts should be made to ensure that high unit costs are contained 
and reduced as far as possible without compromising the quality of care. 
With budgets 100 percent–200 percent of 2014 program spending, optimization suggests that 
investment should continue to be focused on ART and programs for key high-risk populations 
including MSMW and PWID. Spending on key populations with lower incidence (such as FSWs) 
and programs for the low-risk general population (such as HTC) are recommended only for 
higher multiples of the current budget, that is, when optimized spending is approximately 200 
percent of the 2014 program budget. These two spending options are compared in Figure 7.2  
This analysis clearly shows that both increased and optimally allocated spending on HIV 
programs will continue to yield incremental gains in averting new infections and deaths 
(Figure 7.1). 
Figures 18–20 present increases in spending for the program budgets to 120 percent, 150 
percent, and 200 percent, respectively, but not increases in the total HIV response budgets. It 
was assumed that the indirect cost for management and enablers will be stable so these costs 
were fixed as US$ amounts. 
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Figure  7.1 Optimized allocations to minimize HIV incidence and deaths by 2030 at different budget 
levels (2014 budget)* 
 
 
 
Source: Populated Optima model for Georgia. 
Note: * = Only optimized costs are scaled. Nonoptimized spending remains at current levels 
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Figure  7.2 Comparing the allocation of 2014 spending against an optimized allocation of 150 percent 
of current spending  
 
Source: Populated Optima model for Georgia. 
Figure 7.2 compares the current 2014 budget allocation against an optimized allocation of 150 
percent ($19.1 million) of the 2014 spending on direct programs, and assumes that the 
indirect program cost for enablers and management cost would remain stable. The larger 
budget envelope would increase impact by reducing both deaths and new infections (Figure 
7.3). This increased coverage would require additional resources and/or technical efficiency 
gains achieved by reducing the unit costs of programs (without compromising expected 
outcomes).  
Figure  7.3 Comparing the impact on prevalence, deaths, and new infections of 2014 spending against 
an optimized allocation of 150 percent of the 2014 budget  
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Source: Populated Optima model for Georgia. 
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8. HOW MUCH WILL IT COST TO ACHIEVE THE 
TARGETS OF THE NATIONAL HIV 
STRATEGIC PLAN?  
This analysis identifies the minimum resource requirements to achieve the national HIV 
strategy targets and long-term program commitments (chapter 2). The analyses in chapter 6 
assume fixed amounts of available funding and explored an optimized allocation of those funds 
to minimize new infections and deaths with the current budget. In chapter 7, the analyses 
explore the likely gains from increased investment in the HIV response.  
In contrast, the analysis in chapter 8 aims at the full achievement of the 2018 National HIV 
Strategic Plan targets and determines the minimum budget required to achieve these goals 
under an optimized allocation. The impact targets used in this analysis are to contain or reduce 
the current incidence value (<600 per year), to reduce the number of deaths to fewer than 2 
per 100,000 by 2020, and to ensure that at least 75 percent of diagnosed PLHIV are receiving 
ART by 2020 (outcome target). This analysis assesses the gap in funding required to achieve 
these targets.  
Figure  8.1 Minimum annual spending required to meet National HIV Strategic Plan targets (2014 
level)  
 
Source: Populated Optima model for Georgia. 
Figure 8.1 shows 2014 spending, the 2016-18 National HIV Strategic Plan budget, and the 
minimum spending required to achieve the National HIV Strategic Plan impact targets. The 
model results in this section suggest that the National HIV Strategic Plan’s impact could be 
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achieved with approximately 12 percent less funding than the proposed 2018 National HIV 
Strategic Plan budget. To achieve the National HIV Strategic Plan targets, the model findings 
recommend spending an extra 50 percent on MSM programs, 10 percent on HTC and 5 percent 
on ART, shifting the funding by 25 percent from FSW, 40 percent from OST, and 10 percent 
from NSP. The cost savings with respect to the 2018 National HIV Strategic Plan are attributed 
primarily to OST, an area with relatively high unit cost in which higher coverage could be 
obtained within existing budgets. Additional technical efficiency analysis would be required to 
determine whether and how such technical efficiency gains could be achieved. 
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9. WHAT IS THE LONG-TERM FINANCIAL 
COMMITMENT TO HIV SERVICES FOR 
PLHIV? 
This analysis reviews the impact of current and optimized investment choices26 on [pre-
existing?] long-term financial commitments. These commitments are liabilities arising from 
the  need to provide HIV and related health services to PLHIV in the future. In monetary terms, 
a financial commitment is the discounted cost of providing HIV services to PLHIV in a 
particular year. The commitment includes HIV treatment cost, HIV-related health care cost, 
and social mitigation cost.  
Figure  9.1 Annual HIV-related spending for all HIV infections, 2010–30  
 
Source: Populated Optima model for Georgia. 
Figure 9.1 describes the annual costs for HIV treatment and HIV-related care, which are 
derived from the number of PLHIV up to 2030.Figure 9.1 compares the current allocation of 
the 2014 budget to the optimized allocation described in chapter 6. The model predicts that 
the costs of the national response will rise under both allocations, driven by the increases in 
the total number of PLHIV. The analysis estimates that optimizing current allocations could 
save an average of approximately $220,000 annually compared to the current, nonoptimized 
allocations (Figure 9.1). This savings suggests that, although the optimized allocation will keep 
more PLHIV alive, the total long-term cost for the response is lower ($234.9 million compared 
to $234.7 million) due to reduced new infections and reduced HIV-related health care through 
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reduced opportunistic infections. The results also show that, under the optimized allocation of 
current spending (approximately $117 million), financial commitments caused by new 
infections will be $20.7 million, or 15 percent lower than under the current allocation 
(approximately $138 million) (Figure 9.2). 
Figure  9.2 Annual HIV-related spending for all new HIV infections. 2010–30 
 
Source: Populated Optima model for Georgia. 
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10. CONCLUSIONS AND RECOMMENDATIONS 
The Georgian government may be able to better allocate current HIV spending to 
further minimize HIV incidence, prevalence, and HIV-related deaths. 
To assess HIV epidemic trends, the analysts used Optima’s epidemic module calibrated 
to HIV prevalence data points available for different subpopulations in Georgia, 
including key affected populations. The model also was calibrated to data points on the 
number of people on ART from available data sources and in consultation with Georgian 
experts. Analyses using this model highlighted a strong risk that, despite efforts to 
contain the epidemic, prevalence and incidence will continue to increase overall in 
Georgia.  
The expected overall increase in the epidemic appears to be driven by increasing 
incidence and prevalence among MSMW, a key population who currently receive 
only a small portion of the HIV prevention funding. High-risk behaviors in this 
group, including low condom use, call for significant strengthening of interventions targeting 
this key population. Increasing the use of condoms with commercial partners is likely to be an 
effective preventive measure. Additional programs such as pre-exposure prophylaxis (PrEP) 
also could be considered. 
The funding allocations that will be the most effective in containing the epidemic overall 
are those that prioritize the National HIV Strategic Plan targets,27 improve condom use 
among MSMW, and scale up ART to all populations in need. An optimized allocation of 
current funding may reduce long-term financial commitments to the HIV response by 
containing incidence and prevalence. 
Presentation for testing and treatment is delayed, thus increasing costs and 
reducing positive treatment outcomes. These delays are likely to be caused by 
multiple factors. The high rate of out-of-pocket (private) spending on healthcare may 
deter timely and effective care-seeking. Stigma and discrimination may be additional 
significant deterrents in the Georgian context. These deterrents to effective care-seeking may 
add the risk of weak adherence to treatment. Risk factors such as these are best addressed 
with a rights-based approach to care.  
These analyses suggest that diverting funding away from testing in the general 
population and to prevention among MSMW would improve the efficiency of 
current spending levels. The team’s estimations and contextual data suggest that the 
HIV epidemic among PWID is relatively well contained in Georgia due to significant and 
prolonged efforts to target this population. However, even modest reductions in NSP 
allocations increase new infections among PWID. In analyses with limited total HIV response 
budgets, the need to scale up and invest more in ART and MSMW programs implied the need to 
                                                               
27
  This report references the Final Draft NSP targets available in March 2015. (Government of Georgia, 2015).  
1 
2 
3 
4 
5 
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moderately reduce funding for PWID programs. However, due to the risk of rising infections 
among PWID in such a case, it is essential that coverage levels of NSP and OST are sustained 
and expanded. Therefore, as much as possible, key MSMW and PWID populations both should 
be targeted with strong preventive efforts, complemented by comprehensive test-and-offer-
treatment programs.  
Comparing the unit costs of care in Georgia with data from other countries in the 
Region also suggests that greater efficiency in spending could be achieved through 
strategies to reduce the average spending per person reached. This is particularly 
true for OST programs. Care should be taken, however, that these strategies do not 
compromise the current quality of prevention or treatment. Additional analyses of technical 
efficiency are necessary before more robust conclusions can be reached. 
Current annual spending will not be enough to achieve National HIV Strategic Plan 
and international targets. As a result, additional domestic resources will need to be 
allocated to HIV spending to fill resource gaps in the overall HIV budget envelope. 
Although domestic funding for HIV in Georgia has increased since 2006, much of this increase 
has been financed through out-of-pocket (private) expenditure. Reliance on private, out-of-
pocket spending may delay care-seeking, increase the risk of further infections, reduce the cost 
effectiveness of treatment and ultimately reduce the technical efficiency of HIV spending. 
Therefore, when establishing short- or medium-term transitional funding mechanisms to 
supplement and redirect domestic funding sources, emphasis should be placed on increasing 
state participation in healthcare financing. 
By describing the likely trajectories of the HIV epidemic under different conditions, 
highlighting areas of particular risk in the short- to medium-term, and suggesting ways 
to incrementally improve the efficiency of current spending, these suggestions should 
assist Georgia in its current HIV response. Modeling the epidemic in the absence of HIV 
program spending highlighted the significant gains already achieved from current spending in 
new infections and deaths averted. However, analyses of what is needed to achieve the targets 
set by the National HIV Strategic Plan have identified a need for continued and even increased 
investment in an optimized HIV response in Georgia. 
 
6 
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APPENDIXES 
APPENDIX A. TECHNICAL SUMMARY OF OPTIMA 
Appendix A provides a brief technical overview of Optima. A more detailed summary of the 
model and methods is provided elsewhere (Kerr and others 2015). Optima is based on a 
dynamic, population-based HIV model. Figure A.1a summarizes the populations and mixing 
patterns used in Optima. Figure A.1b shows the disease progression implemented in the 
model. Optima tracks the entire population of people living with HIV (PLHIV) across 5 stages 
of CD4 count. These CD4 count stages are aligned with the progression of the World Health 
Organization (WHO) treatment guidelines, namely, acute HIV infection, >500, 350–500, 200–
350, 50–200, and 50 cells per microliter. Key aspects of the antiretroviral therapy (ART) 
service delivery cascade are included: from infection to diagnosis, ART initiation on first-line 
therapy, treatment failure, subsequent lines of therapy, and HIV/AIDS-related or other death.   
Figure A.1a Example population groups and HIV transmission-related interactions in Optima  
 
Source: Graphic prepared by UNSW study team.  
The model uses a linked system of ordinary differential equations to track the movement of 
PLHIV among HIV health states. The full set of equations is provided in the supplementary 
material to a summary paper on the Optima model. The overall population is partitioned in 
two ways: by population group and by HIV health state. Individuals are assigned to a given 
population group based on their dominant risk.28 HIV infections occur through the interactions 
among different populations by regular, casual, or commercial (including transactional) sexual 
partnerships; through sharing of injecting equipment; or through mother-to-child 
transmission. The force-of-infection is the rate at which uninfected individuals become 
infected. The rate depends on the number and type of risk events to which individuals are 
exposed in a given period (either within their population groups or through interaction with 
other population groups) and the infection probability of each event. Mathematically, the force 
of- infection has the general form:  
 
where λ is the force-of-infection, β is the transmission probability of each event, and n is the 
effective number of at-risk events (that is, n gives the average number of interaction events 
with HIV-infected people through which HIV transmission may occur). The value of the 
                                                               
28  However, to capture important cross-modal types of transmission, relevant behavioral parameters can be set to 
non-zero values (for example, males who inject drugs may engage in commercial sex; some MSM may have 
female sexual partners). 
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transmission probability β varies across CD4 count compartments (indirectly reflecting the 
high viral load at early and late stages of infection); differs for different modes of transmission 
(intravenous drug injection with a contaminated needle-syringe, penile-vaginal or penile-anal 
intercourse, and mother-to-child); and may be reduced by behavioral interventions (for 
example, condom use), biological interventions (for example, male circumcision), or ART. 
There is one force-of-infection term for each type of interaction, for example, casual sexual 
relationships between male sex workers and female sex workers (FSW). The force-of-infection 
for a given population will be the sum of all interaction types.29 In addition to the force-of-
infection rate, which is the number of individuals who become infected with HIV per year, 
there are seven other ways by which individuals can change health states.30 The change in the 
number of people in each compartment is determined by the sum over the relevant rates 
described above multiplied by the population size of the compartments on which they act.31 
                                                               
29  For sexual transmission, the force-of-infection is determined by:  
 HIV prevalence (weighted by viral load) in partner populations  
 Average number of casual, regular, and commercial homosexual and heterosexual acts per person per year 
 Proportion of these acts in which condoms are used  
 Proportion of men who are circumcised  
 Prevalence of sexually transmissible infections (which can increase HIV transmission probability)  
 Proportion of acts that are covered by pre-exposure prophylaxis and post-exposure prophylaxis 
 Proportion of partners on antiretroviral treatment (art)  
 Efficacies of condoms, male circumcision, post-exposure prophylaxis, pre-exposure prophylaxis, and art at 
preventing HIV transmission.  
 For injecting-related transmission, the force-of-infection is determined by: 
 HIV prevalence (weighted by viral load) in populations of people who use a syringe and then share it 
 Number of injections per person per year 
 Proportion of injections made with shared equipment 
 Fraction of people who inject drugs on opioid substitution therapy and its efficacy in reducing injecting 
behavior. 
 For mother-to-child transmission, the number of-infections is determined by: 
 Birth rate among women living with HIV 
 Proportion of women with HIV who breastfeed 
 Probability of perinatal HIV transmission in the absence of intervention  
 Proportion of women receiving prevention of mother-to-child transmission (PMTCT), including ART. 
30  First, individuals may die, either because of an average background death rate for that population (which is 
greater for older populations or for people who inject drugs) or because of HIV/AIDS (which depends on CD4 
count). Second, in the absence of treatment, individuals progress from higher to lower CD4 counts. Third, 
individuals can move from undiagnosed to diagnosed states based on their HIV testing rate, which depends on 
CD4 count (for example, people with AIDS symptoms or primary HIV infection may have a higher testing rate) 
and population type (for example, FSW may test more frequently than males in the general population). Fourth, 
diagnosed individuals may commence ART at a rate depending on CD4 count. Fifth, individuals may experience 
treatment failure due to lack of adherence to therapy or development of drug resistance. Sixth, people may 
initiate second and subsequent lines of treatment after treatment failure. Finally, while on successful first- or 
second-line treatment (that is, effective viral suppressive therapy), individuals may progress from lower to 
higher CD4 counts. 
31  For example, the change in the number of undiagnosed HIV-positive FSW with a CD4 count between 200–350 
cells per microliter is:  
 
 where UFSW2002350 is the current number of undiagnosed HIV-positive FSW with a CD4 count between 200–
350 cells per microliter; UFSW3502500 is the same population but with higher CD4 count (350–500 cells/mL); t 
is the disease progression rate for the given CD4 count (where 1/t is the average time to lose 150 CD4 cells/mL); 
m is the death rate; and h is the HIV testing rate. (Note: This example does not consider movement among 
populations, such as FSW returning to the general female population and vice versa—something which is 
included in Optima.)  
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Figure A.1b Schematic diagram of the health state structure of the model  
 
Source: Figure prepared by UNSW study team. 
Note: Each compartment represents a single population group with the specified health state. Each arrow 
represents the movement of numbers of individuals among health states. All compartments except for 
“susceptible” represent individuals living with HIV. Death includes all causes of death. 
Each compartment (Figure A.1b, boxes) corresponds to a single differential equation in the 
model, and each rate (Figure A.1b, arrows) corresponds to a single term in that equation. Table 
A.1 lists the parameters used in Optima; most of these are used to calculate the force of 
infection. The analysts interpret empirical estimates for model parameter values in Bayesian 
terms as previous distributions. The model then must be calibrated: finding posterior 
distributions of the model parameter values so+ that the model generates accurate estimates 
of HIV prevalence, the number of people on treatment, and any other epidemiological data that 
are available (such as HIV-related deaths). The calibration can be performed automatically, 
manually, or a combination. Model calibration and validation normally should be performed in 
consultation with governments in the countries in which the model is being applied. 
Table A.1 Input parameters of the model 
 Biological parameters Behavioral parameters 
Epidemiological/Other 
parameters 
Population 
parameters 
Background death rate  Population sizes (T, P) 
HIV-related 
parameters 
Sexual HIV transmission 
probabilities*  
STI-related transmissibility 
increase* 
Condom efficacy* 
Circumcision efficacy* 
HIV health state progression 
rates (H) 
HIV-related death rates (H) 
Number of sexual partners* (T, P, S) 
Number of acts per partner* (S) 
Condom usage probability* (T, P) 
Circumcision probability* (T) 
HIV prevalence (T, P) 
STI prevalence (T, P) 
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Table A.1 Input parameters of the model (Continued) 
 Biological parameters Behavioral parameters 
Epidemiological/Other 
parameters 
MTCT 
parameters 
Mother-to-child transmission 
probability* 
Birth rate* 
PMTCT access rate* (T) 
 
 
Injecting HIV 
transmissibility* 
Syringe cleaning efficacy* 
Drug-related death rate 
Number of injections* (T) 
Syringe sharing probability* (T) 
Syringe cleaning probability* 
Methadone treatment probability (T) 
 
Treatment 
parameters 
ART efficacy in reducing 
infectiousness* 
ART failure rates 
HIV testing rates (T, P, H) 
Number of people on 
ART 
Economic 
parameters 
Health utilities  
Costs of all prevention, 
care and treatment 
programs, enablers and 
management (T, I) 
Discounting and inflation 
rates (T) 
Health care costs 
Source: UNSW study team. 
Note: * = Parameter is used to calculate the force of infection; H=Parameter depends on health state; I = 
Parameter depends on intervention type; P=Parameter depends on population group; S = Parameter depends 
on sexual partnership type; T = Parameter value changes over time.  
HIV Resource Optimization and Program Coverage Targets 
A novel component of Optima is its ability to calculate allocations of resources that optimally 
address one or more HIV-related objectives (for example, impact-level targets in a country’s 
HIV national strategic plan). Because this model also calculates the coverage levels required to 
achieve these targets, Optima can be used to inform HIV strategic planning and the 
determination of program coverage levels. The key assumptions of resource optimization are 
the relationships among (1) the cost of HIV programs for specific target populations, (2) the 
resulting coverage levels of targeted populations with these HIV programs, and (3) how these 
coverage levels of HIV programs for targeted populations influence behavioral and clinical 
outcomes. Such relationships are required to understand how incremental changes in 
spending (marginal costs) affect HIV epidemics.32 Logistic functions can incorporate initial 
start-up costs and enable changes in behavior to saturate at high spending levels, thus better 
reflecting program reality. The logistic function has the form: 
where L(x) relates spending to coverage; x is the amount of funding for the program; A is the 
lower asymptote value (adjusted to match the value of L when there is no spending on a 
program); B is the upper asymptote value (for very high spending); C is the midpoint; and D is 
the steepness of the transition from A to B. For its fits, the team typically chose saturation 
values of the coverage to match behavioral data in countries with heavily funded HIV 
                                                               
32  A traditional approach is to apply unit cost values to inform a linear relationship between money spent and 
coverage attained. This assumption is reasonable for programs such as an established ART program that no 
longer incurs start-up or initiation costs. However, the assumption is less appropriate for condom promotion and 
behavior change communication programs. Most HIV programs typically have initial setup costs, followed by a 
more effective scale-up with increased funding. However, very high coverage levels have saturation effects 
because these high levels require increased incremental costs due to generating demand and related activities for 
the most difficult-to-reach groups. Optima uses a logistic function fitted to available input data to model cost–
coverage curves (Appendix 2). 
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responses.33 To perform the optimization, Optima uses a global parameter search algorithm 
called Bayesian adaptive locally linear stochastic descent (BALLSD). BALLSD is similar to 
simulated annealing in that it makes stochastic downhill steps in parameter space from an 
initial starting point. However, unlike simulated annealing, BALLSD chooses future step sizes 
and directions based on the outcome of previous steps. For certain classes of optimization 
problems, the team has shown that BALLSD can determine optimized solutions with fewer 
function evaluations than traditional optimization methods, including gradient descent and 
simulated annealing. 
While all HIV interventions have some direct or indirect non-HIV benefits, some programs 
including opiate substitution therapy (OST) or conditional cash transfers, have multiple 
substantial proven benefits across different sectors. Such additional benefits were reflected by 
using the approach of a cross-sectoral financing model to effectively distribute the costs in 
accordance with the benefits. By adapting standard techniques from welfare economics to 
attribute the benefits of OST programs across the benefiting sectors, it was estimated that 
average HIV-related benefits are approximately only 10 percent of the overall health and social 
benefits of OST. Therefore, only 10 percent of the OST cost was included in the optimization 
analysis. 
Uncertainty Analyses 
Optima uses a Markov chain Monte Carlo (MCMC) algorithm for performing automatic 
calibration and for computing uncertainties in the model fit to epidemiological data. With this 
algorithm, the model is run many times (typically, 1,000–10,000) to generate a range of 
epidemic projections. Their differences represent uncertainty in the expected epidemiological 
trajectories. The most important assumptions in the optimization analysis are associated with 
the cost-coverage and coverage-outcome curves. To incorporate uncertainty in these curves, 
users define upper and lower limits for both coverage and behavior for no spending and for 
very high spending.34 
                                                               
33  Program coverage for zero spending, or behavioral outcomes for zero coverage of formal programs, is inferred 
using data from early on in the epidemic or just before significant investment in HIV programs. Practically, the 
team also discussed the zero and high spending cases with local experts, who could advise on private sector HIV 
service delivery outside the governments’ expenditure tracking systems. For each HIV program, the team derived 
one set of logistic curves that related funding to program coverage levels and another set of curves (generally, 
linear relationships) that related coverage levels to clinical or behavioral outcomes (the impacts that HIV 
strategies aim to achieve). 
34  All available historical spending data and achieved outcomes of spending, data from comparable settings, 
experience, and extensive discussion with stakeholders in the country of application can be used to inform these 
ranges. All logistic curves within these ranges then are allowable and are incorporated in Optima uncertainty 
analyses. These cost-coverage and coverage-outcome curves thus are reconciled with the epidemiological, 
behavioral, and biological data in a Bayesian optimal way, thereby enabling the calculation of unified uncertainty 
estimates. 
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APPENDIX B.  CALIBRATION FIGURES  
Figure B.1 Calibration of HIV prevalence among key populations, 2000–30a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: a = Black dots represent available data for the number of people on ART. Lines attached to these discs 
represent uncertainty bounds. The solid curve is the best-fitting simulation of total ART patient numbers. 
The combination of relatively late diagnosis and high number of PLHIV, together with low 
testing rate suggests that there is a higher number of PLHIV than currently diagnosed. 
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Therefore the upper-bounds of the data points were chose as the best fit for MSMW, PWID, 
FSW and females 15-49. The stabilization of the curve for PWID is driven by behavioral 
data and risk reduction such as reduced needle sharing. The data points for FSW are highly 
variable and an upper data point was chosen to fit with the registered number of females 
living with HIV. 
Figure B.2 Calibration of model to overall HIV prevalence, 2000–30 
 
Figure B.3 Calibrated overall Incidence of HIV, 2000–30 
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Figure B.4 Calibrated number of DALYs, diagnoses, first and subsequent lines of treatment, 2000–30 
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APPENDIX C. COST-COVERAGE-OUTCOME CURVES 
Table C.1 Selected behaviors affected by HIV programs 
HIV Program Targeted behavior 
Programs for female sex workers and clients 
(package) 
Proportion of FSW who are tested for HIV each year 
Proportion of sexual acts in which condoms are used with 
commercial partners – FSW and clients 
Programs for men who have sex with men 
and women (package) 
Proportion of sexual acts in which condoms are used with 
regular partners by MSMW 
Proportion of sexual acts in which condoms are used with casual 
partners by MSMW 
Proportion of MSMW who are tested for HIV each year 
Opiate substitution therapy Number of people on OST 
Needle-syringe program (NSP) and other 
prevention for PWID (package) 
Proportion of injections using receptively shared needle-
syringes 
Proportion of PWID who are tested for HIV each year 
HIV testing and counselling 
Proportion of males 15–49 who are tested for HIV each year 
Proportion of females 15–49 who are tested for HIV each year  
Proportion of males 50+ who are tested for HIV each year 
Proportion of females 50+ who are tested for HIV each year 
Antiretroviral therapy Number of people on ART 
Prevention of mother-to-child transmission Proportion of pregnant women covered with PMTCT 
Figure C.1 FSW: Proportion who are tested for HIV each year  
  
Figure C.2 FSW: Proportion of sexual acts in which condoms are used with commercial partners 
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Figure C.3 FSW: Proportion of sexual acts in which condoms are used with commercial partners 
(clients) 
  
Figure C.4 MSM: Proportion of MSM sexual acts in which condoms are used with regular partners 
  
Figure C.5 MSM: Proportion of sexual acts in which condoms are used with casual partners 
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Figure C.6 MSM: Proportion who are tested for HIV each year 
  
Figure C.7 Opiate substitution therapy: Number of people covered 
 
Figure C.8 PWID: Proportion of injections using receptively shared needle-syringes 
 
Figure C.9 PWID: Proportion who are tested for HIV each year 
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Figure C.10 Males 15–49: Proportion who are tested for HIV each year 
 
Figure C.11 Females 15–49: Proportion who are tested for HIV each year 
 
Figure C.12 Males 50+: Proportion who are tested for HIV each year 
 
Figure C.13 Females 50+: Proportion who are tested for HIV each year 
 
  
Appendix C 55 
 
Figure C.14 Antiretroviral therapy: Number of people covered 
 
Figure C.15 PMTCT: Proportion of people covered 
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APPENDIX D. DATA TABLES 
Appendix D.1 Data Tables, 2000–14  
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
FSW 
High – – – – – – – – – – – – – – 7 – 
Best – – – – – – – – – – – – – – 7 – 
Low – – – – – – – – – – – – – – 6 – 
Clients 
High – – – – – – – – – – – – – – – 167 
Best – – – – – – – – – – – – – – – 111 
Low – – – – – – – – – – – – – – – 56 
MSMW 
High – – – – – – – – – – – – – – 20 – 
Best – – – – – – – – – – – – – – 17 – 
Low – – – – – – – – – – – – – – 8 – 
PWID 
High – – – – – – – – – 41 – – – –  – 
Best – – – – – – – – – 40 – – – – 45 – 
Low – – – – – – – – – 39 – – – – – – 
Males 15–49 Best 920 916 909 905 903 910 946 948 949 910 951 952 954 941 880 – 
Females 15–49 Best 1166 1162 1153 1149 1148 1153 1180 1181 1172 1164 1166 1161 1156 1134 1120 – 
Males 50+ Best 513 511 508 514 515 521 537 545 554 563 578 593 606 616 626 – 
Females 50+ Best 711 708 704 710 714 722 741 754 765 780 797 815 832 843 859 – 
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Table D.2 HIV prevalence, 2000–14 (%) 
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
FSW Best – – – – 1.30 – – – – 1.90 – – 1.30 – 0.60 – 
Clients Best – – – – – – – – – – – –   – – – 
MSMW 
High – – – – – – – – – – – – 18.70.0 – – – 
Best – – – – – 4.30 – 3.70 – – 7.00 – 13.00.0 – – – 
Low – – – – – – – – – – – – 8.50 – – – 
PWID 
High 1.10 – 1.10 – 2.10 – 3.60 – – 4.50 – –   – – – 
Best 1.10 – 1.10 – 1.50 – 1.80 – – 2.40 – – 3.00 – – – 
Low 1.10 – 1.1 – 0.40 – 0.00 – – 2.10 – – – – – – 
Males 15–49 Best – – – – – – – – – – – – – – – 0.07 
Females 15–49 Best – – – – – – – – – 0.03 0.03 0.03 0.03 0.06 – – 
Males 50+ Best – – – – – – – – – – – – – – – 0.02 
Females 50+ Best – – – – – – – – – – – – – – – 0.02 
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Table D.3 Testing and treatment 
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
Testing rate per 
year (%) 
FSW (%) – – – – – – 33 – – – – 28 42 42 – – 
Clients – – – – – – – – – – – – – – – – 
MSMW (%) – – – – – 27 – 30 – – 26 26 34 34 – – 
PWID (%) – – – – – – – – – – – 57 15 15 – – 
Males 15–49 (%) – – – – – – – – – – 6 – – – – – 
Females 15–49 
(%) 
– – – – – – – – – – 6 – – – – – 
Males 50+ (%) – – – – – – – – – – 2 – – – – – 
Females 50+ (%) – – – – – – – – – – 2 – – – – – 
Probability being tested 
with CD4 <200 per year 
High (%) – – – – – – – – – – – – – – – 30 
Average (%) – – – – – – – – – – – – – – – 65 
Low (%) – – – – – – – – – – – – – – – 80 
Number on first-line treatment 0 0 0 0 51 143 235 315 457 606 764 1033 1326 1687 1998 – 
Number on subsequent lines of treatment 0 0 0 0 0 7 31 31 41 49 66 89 130 160 230 – 
Treatment eligibility criterion 200 200 200 200 200 200 200 200 200 200 200 250 350 500 500 – 
% covered by  
pre-exposure 
prophylaxis 
FSW 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
Clients 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
MSMW 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
PWID 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
Males 15–49 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
Females 15–49 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
Males 50+ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
Females 50+ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 – – 
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Table D.3 Testing and treatment (Continued) 
            
 
 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
% of women on PMTCT  
(Option B/B+) 
 – – – – – – – – – 80.80 82.10 82.30 85.80 86.00 – – 
Birth rate 
FSW 0.046 0.045 0.045 0.046 0.046 0.047 0.049 0.050 0.051 0.052 0.053 0.052 0.052 – – – 
Females 15–49 0.046 0.045 0.045 0.046 0.046 0.047 0.049 0.050 0.051 0.052 0.053 0.052 0.052 – – – 
Females 50+ – – – – – – – – – – – – – – – 0.00 
% HIV-positive women 
who breastfeed 
 – – – – – – – – – – – – – – – 12 
 
Table D.4 Optional indicators 
               
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Number of HIV tests per year  – – – – 24.31 26.03 16.99 16.99 18.79 17.56 25.37 21.80 15.56 18.09 – 
Number of HIV diagnoses per year  79 93 95 100 163 242 276 344 351 385 455 424 526 490 564 
Modeled estimate of new HIV 
infections per year  
255 301 356 405 461 503 542 575 627 649 691 718 679 639 – 
Modeled estimate of HIV prevalence  0.04 0.05 0.06 0.07 0.09 0.10 0.12 0.14 0.16 0.18 0.20 0.23 0.25 0.27 – 
Number of HIV-related deaths  34 44 56 71 86 84 78 79 99 109 129 157 147 110 – 
Number of people initiating ART 
each year 
– – – – 52 130 136 135 195 229 238 389 431 523 520 
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Table D.5 Sexual acts per person per year 
            
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
Average 
number of 
regular 
sexual acts 
FSW  – – – – – – – – – – – – 66.24 – 38.40 – 
Clients – – – – – – – – – – – – – – – 54 
MSMW – – – – – – – – – – 19.5 – 15.42 – – – 
PWID – – – – – – – – – – – – – – – 54 
Males 15–49 – – – – – – – – – – – – – – – 54 
Females 15–49 – – – – – – – – – – – – – – – 54 
Males 50+ – – – – – – – – – – – – – – – 27 
Females 50+ – – – – – – – – – – – – – – – 27 
Average 
number of 
casual sexual 
acts 
FSW – – – – – – – – – – – – – – – 15 
Clients – – – – – – – – – – – – – – – 6 
MSMW – – – – – – – – – – 60.0 – 60.0 – – – 
PWID – – – – – – – – – – – – – – – 12 
Males 15–49 – – – – – – – – – – – – – – – 6 
Females 15–49 – – – – – – – – – – – – – – – 6 
Males 50+ – – – – – – – – – – – – – – – 3 
Females 50+ – – – – – – – – – – – – – – – 1 
Average 
number of  
commercial 
sexual 
acts 
FSW – – 494 
 
572 
 
546 – – – – – 426.4 – 554.8 – 
Clients – – – – – – – – – – – – – – – 33 
MSMW – – – – – – – – – – – – – – – – 
PWID – – – – – – – – – – – – – – – 33 
Males 15-49 – – – – – – – – – – – – – – – 0 
Females 15-49 – – – – – – – – – – – – – – – 0 
Males 50+ – – – – – – – – – – – – – – – 0 
Females 50+ – – – – – – – – – – – – – – – 0 
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Table D.6 Condom use and circumcision probability 
            
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
Condom use 
% for 
regular 
acts 
FSW – – – – – – – – – – – – 66.24 – 38.40 – 
Clients – – – – – – – – – – – – – – – 54 
MSMW – – – – – – – – – – 19.5 – 15.42 – – – 
PWID – – – – – – – – – – – – – – – 54 
Males 15–49 – – – – – – – – – – – – – – – 54 
Females 15–49 – – – – – – – – – – – – – – – 54 
Males 50+ – – – – – – – – – – – – – – – 27 
Females 50+ – – – – – – – – – – – – – – – 27 
Condom use 
% for casual 
acts 
FSW – – – – – – – – – – – – – – – 15 
Clients – – – – – – – – – – – – – – – 6 
MSMW – – – – – – – – – – 60.0 – 60.0 – – 
 
PWID – – – – – – – – – – – – – – – 12 
Males 15–49 – – – – – – – – – – – – – – – 6 
Females 15–49 – – – – – – – – – – – – – – – 6 
Males 50+ – – – – – – – – – – – – – – – 3 
Females 50+ – – – – – – – – – – – – – – – 1 
Condom use 
% for 
commercial 
acts 
FSW – – 494 – 572 – 546 – – – – – 426.4 
 
554.8 – 
Clients – – – – – – – – – – – – – – – 33 
MSMW – – – – – – – – – – – – – – – – 
PWID – – – – – – – – – – – – – – – 33 
Males 15-49 – – – – – – – – – – – – – – – 0 
Females 15-49 – – – – – – – – – – – – – – – 0 
Males 50+ – – – – – – – – – – – – – – – 0 
Females 50+ – – – – – – – – – – – – – – – 0 
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Table D.6 Condom use and circumcision probability (Continued) 
          
  
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
Circumcision 
probability 
Clients – – – – – – – – – – – – – – – 0 
MSMW – – – – – – – – – – – – – – – 0 
PWID – – – – – – – – – – – – – – – 0 
Males 15–49 – – – – – – – – – – – – – – – 0 
Males 50+ – – – – – – – – – – – – – – – 0 
 
  
Table D.7 Non-HIV deaths, sexually transmitted infections, and tuberculosis prevalence 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
% People die 
from non-HIV-
related causes 
per year 
FSW (%) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0. 0.2 0.2 0.2 0.2 – 
Clients (%) 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 – 
MSMW (%) 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 – 
PWID (%) 1.8 1.8 1.8 1.8 1.8 1.7 1.7 1.7 1.7 1.7 1.6 1.6 1.6 1.6 1.7 – 
Males 15–49 (%) 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 – 
Females 15–49 
(%) 
0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 – 
Males 50+ (%) 3.5 3.5 3.5 3.5 3.5 3.7 3.7 3.6 3.6 3.5 3.6 3.8 3.7 3.7 3.6 – 
Females 50+ (%) 2.8 2.8 2.9 2.9 2.8 2.9 2.9 2.9 2.8 2.8 2.9 3.1 3.0 2.9 2.9 – 
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Table D.7 Non-HIV deaths, sexually transmitted infections, and tuberculosis prevalence (Continued) 
 
 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Assumption 
Prevalence of 
ulcerative STIs 
FSW (%) – – 28.8 – 48.7 – 23.8 – – 45.5 – – 34.6 – – – 
Clients (%) – – – – – – 
 
– – – – – – – – 10 
MSMW (%) – – – – – – 27.1 – – – 10.9 – 32.9 – – – 
PWID (%) – – – – – – – – – – – – – – – 5 
Males 15–49 (%) – – – – – – – – – – – – – – – 3 
Females 15–49 (%) – – – – – – – – – – 2.6 – – – – – 
Males 50+ (%) – – – – – – – – – – – – – – – 1 
Females 50+ (%) – – – – – – – – – – – – – – – 1 
Prevalence of 
discharging 
STIs 
FSW (%) – – 25.3 – 22.3 – 21.4 – – 5.7 – – 14.4 – – – 
Clients (%) – – – – – – – – – – – – – – – 10 
MSMW (%) – – – – – – – – – – – – – – – 2 
PWID (%) – – – – – – – – – – – – – – – 5 
Males 15–49 (%) – – – – – – – – – – – – – – – 2 
Females 15–49 (%) – – – – – – – – – – – – – – – 4 
Males 50+ (%) – – – – – – – – – – – – – – – 1 
Females 50+ (%) – – – – – – – – – – – – – – – 1 
Tuberculosis 
prevalence 
FSW (%) – – – – – – – – – – – – – – – 0.08 
Clients (%) – – – – – – – – – – – – – – – 0.18 
MSMW (%) – – – – – – – – – – – – – – – 0.18 
PWID (%) – – – – – – – – – – – – –   0.8 – 
Males 15–49 (%) – – – – – – – – – – – – – 0.18 – – 
Females 15–49 (%) – – – – – – – – – – – – – 0.08 – – 
Males 50+ (%) – – – – – – – – – – – – – – – 0.18 
Females 50+ (%) – – – – – – – – – – – – – – – 0.08 
O
p
tim
izin
g in
vestm
en
ts in
 G
eo
rgia’s H
IV
 resp
o
n
s e 
  
 
6
4 
Table D.8 Injecting drug use parameters 
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Assumption 
Average no. 
injections/ 
person/year 
FSW – – – – – – – – – – – – – – 0 
Clients – – – – – – – – – – – – – – 0 
MSMW – – – – – – – – – – – – – – 0 
PWID – – – – – – – – – – – – – – 180 
Males 15–49 – – – – – – – – – – – – – – 0 
Females 15-49 – – – – – – – – – – – – – – 0 
Males 50+ – – – – – – – – – – – – – – 0 
Females 50+ – – – – – – – – – – – – – – 0 
Drug use 
parameters 
% shared injections – – 10 – 14 – – 6 – 3 – – 5 – – 
PWID on OST – –   – – – – – – 1,599 1,920 1,760 2,080 4,635 – 
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Table D.9 Transitions 
  
FSW Clients MSMW PWID 
Males 
15–49 
Females 
15–49 
Males 
50+ 
Females 
50+ 
Age-related 
transitions 
FSW – – – – – – – 25 
Clients – – – – – – 25 – 
MSMW – – – – – – 25 – 
PWID – – – – – – 25 – 
Males 15–49 – – – – – – 35 – 
Females 15–49 – – – – – – – 35 
Males 50+ – – – – – – – – 
Females 50+ – – – – – – – – 
Risk-related 
transitions 
FSW – – – – – 20 – – 
Clients – – – – 25 – – – 
MSMW – – – – – – – – 
PWID – – – – 25 – – – 
Males 15–49 – – – – – – – – 
Females 15–49 – – – – – – – – 
Males 50+ – – – – – – – – 
Females 50+ – – – – – – – – 
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Table D.10 Partnerships 
 FSW Clients MSMW PWID 
Males 
15–49 
Females 
15–49 
Males 
50+ 
Females 
50+ 
Regular 
sexual 
interactions 
FSW – – – – – – – – 
Clients 10 – – – – 1 – 0 
MSMW – – 0 – – 1 – – 
PWID 10 – – – – 1 – – 
Males 15–49 0.1 – – – – 1 – – 
Females 15–49 – – – – – – – – 
Males 50+ 0.1 – – – – – – 1 
Females 50+ – – – – – – – – 
Casual sexual 
interactions 
FSW – – – – – – – – 
Clients 10 – – – – 1 – – 
MSMW – – 1 – – 0 – – 
PWID 10 – – – – 1 – – 
Males 15–49 0.1 – – – – 10 – 1 
Females 15–49 – – – – – – – – 
Males 50+ 0.1 – – – – 1 – 2 
Females 50+ – – – – – – – – 
Commercial 
sexual 
interactions 
FSW – – – – – – – – 
Clients 1 – – – – – – – 
MSMW 0 – 1 – – – – – 
PWID 0 – – – – – – – 
Males 15–49 0 – – – – – – – 
Females 15–49 – – – – – – – – 
Males 50+ 0 – – – – – – – 
Females 50+ – – – – – – – – 
Injecting 
interactions 
FSW – – – – – – – – 
Clients – – – – – – – – 
MSMW – – – – – – – – 
PWID – – – 1 – – – – 
Males 15–49 – – – – – – – – 
Females 15–49 – – – – – – – – 
Males 50+ – – – – – – – – 
Females 50+ – – – – – – – – 
FSW – – – – – – – – 
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APPENDIX E. GLOSSARY 
Allocative efficiency 
(AE) 
Within a defined resource envelope, AE of health or HIV-specific 
interventions provides the right intervention to the right people at the right 
place in the correct way to maximize targeted health outcomes.  
Behavioral 
intervention 
Discourages risky behaviors and reinforces protective ones, typically by 
addressing knowledge, attitudes, norms, and skills.  
Biomedical 
intervention 
Biomedical HIV intervention strategies use medical and public health 
approaches to block infection, decrease infectiousness, and reduce 
susceptibility.  
Bottom-up costing Costing method that identifies all of the resources that are used to provide a 
service and assigns a value to each of them. These values then are summed 
and linked to a unit of activity to derive a total unit cost.  
Cost-effectiveness 
analysis (CEA) 
Form of economic analysis that compares the relative costs and outcomes 
(effects) of two or more courses of action.  
Effectiveness Degree of achievement of a (health) outcome in a real-world 
implementation setting.  
Efficiency  Achievement of an output with the lowest possible input without 
compromising quality.  
Financial 
sustainability  
Ability of government and its partners to continue spending on a health or 
HIV outcome for the required duration and to meet any cost of borrowing 
without compromising the government’s, household’s, or other funding 
partner’s financial position.  
HIV incidence Estimated total number (or rate) of new (total number of diagnosed and 
undiagnosed) HIV infections in a given period.  
HIV prevalence Percentage of people who are infected with HIV at a given point in time.  
Implementation 
efficiency  
Set of measures to ensure that programs are implemented in a way that 
achieves outputs with the lowest input of resources. In practical terms, 
improving implementation efficiency means identifying better delivery 
solutions. Doing so requires improving planning, designing service delivery 
models, and assessing and addressing service delivery “roadblocks.” 
Implementation efficiency will improve the scale, coverage, and quality of 
programs.  
Incremental cost-
effectiveness ratio 
(ICER) 
Equation commonly used in health economics to provide a practical 
approach to decision making regarding health interventions. ICER is the 
ratio of the change in costs to incremental benefits of a therapeutic 
intervention or treatment.  
Model Computer system designed to demonstrate the probable effect of two or 
more variables that might be brought to bear on an outcome. Such models 
can reduce the effort required to manipulate these factors and present the 
results in an accessible format.  
Opioid substitution 
therapy (OST) 
Medical procedure of replacing an illegal opioid, such as heroin, with a 
longer acting but less euphoric opioid. Methadone or buprenorphine 
typically are used, and the drug is taken under medical supervision.  
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Opportunistic infection 
under medical 
(OI prophylaxis) 
Treatment given to PLHIV to prevent either a first episode of an OI 
(primary prophylaxis) or the recurrence of infection (secondary 
prophylaxis).  
Pre-exposure 
prophylaxis (PrEP) 
Method for people who do not have HIV but are at substantial risk of 
acquiring it to prevent HIV infection by taking an antiretroviral drug.  
Program effectiveness  Program effectiveness incorporates evaluations to establish what works 
and impacts disease and/or transmission intensity, disseminating 
proven practice, and improving the public health results of programs.  
Program sustainability  Ability to maintain the institutions, management, human resources, 
service delivery, and demand generation components of a national 
response until impact goals have been achieved and maintained over 
time as intended by the strategy.  
Return on investments 
(ROI) 
Performance measure used to evaluate the efficiency of an investment 
or to compare the efficiency of a number of different investments. To 
calculate ROI, the benefit (return) of an investment is divided by the cost 
of the investment; the result is expressed as a percentage or a ratio.  
Saturation Maximum level of coverage that a program can achieve.  
Technical efficiency  Delivery of a (health) service in a way that produces maximum output at 
the lowest possible unit cost while according with operational quality 
standards.  
Top-down costing Costing method that divides total expenditure (quantum of funding 
available) for a given area or policy by total units of activity (such as 
patients served) to derive a unit cost.  
Universal health 
coverage (UC) 
Universal health coverage (UC), is defined as ensuring that all people 
have access to the promotive, preventive, curative, rehabilitative, and 
palliative health services that they need, of sufficient quality to be 
effective, while ensuring that the use of these services does not expose 
the user to financial hardship. 
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